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Summary	  
 
An enantioselective synthesis of the antifungal natural product (+)-ambruticin S 
has been accomplished in our group. For the synthesis of a ring A lactone fragment, 
three approaches were developed. They all started from commercially available and 
inexpensive methyl α-D-glycopyranoside, which already possesses the required diol unit. 
A deletion of the hydroxyl group at C-4 and a one-carbon homologation of the C-6 side 
chain furnished the ring A lactone.  
 
The second project is an ongoing collaboration between the Hanessian group and 
ISIS pharmaceuticals to develop new antisense oligonucleosides.  The cis- and 
trans-[4.3.0]bicyclic antisense nucleosides were successfully synthesized from a 
common natural monosaccharide, L-arabinose, which bears the required stereocenters. A 
key Sakurai allylation led to the cis- and trans diastereomers under Felkin-Ahn and 
chelation-controlled conditions respectively. The final bicyclic targets were achieved by 
a practical proline-catalyzed	   intramolecular aldol reaction and ring-closing metathesis 
(RCM) strategy, and application of the Vorbrüggen method for nucleoside synthesis.  
 
Keywords: (+)-Ambruticin S, methyl α-D-glycopyranoside, [4.3.0]bicyclic antisense 
nucleoside, L-arabinose, Sakurai allylation, intramolecular aldol reaction, Ring-Closing 
Metathesis (RCM), Vorbrüggen glycosylation. 
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Résumé 
 
La synthèse énantiosélective de la (+)-ambruticine S, un produit naturel 
antifongique a été effectuée au sein de notre groupe. Trois approches ont été 
développées pour la synthèse du fragment lactone (cycle A). Ces trois voies d’accès au 
cycle A ont pour intermédiaire commun le methyl α-D-glycopyranoside déjà porteur du 
diol requis et disponible commercialement à bon prix. Une désoxygénation de 
l’hydroxyle en C-4 et l’homologation d’un carbone de la chaine latérale en C-6 ont 
permis l’obtention du cycle lactonique A. 
 
Le deuxième projet est une collaboration entre le groupe Hanessian et ISIS 
Pharmaceuticals afin de développer de nouveaux oligonucléosides antisens. Les 
nucléosides antisens [4.3.0]-bicycliques cis et trans ont été synthétisés avec succès  à 
partir d’un monosaccharide naturel commun, L-arabinose, porteur des stéréocentres 
requis. Un réaction clé d’allylation de Sakurai a permis d’obtenir les diastéréoisomères 
cis et trans  dans des conditions de contrôle de type Felkin-Ahn et de contrôle par 
chélation respectivement. Les composés bicycliques finaux cibles ont été obtenus par 
une réaction d’aldol intramoléculaire catalyzéé par la proline, par métathèse de 
fermeture de cycle et par l’application de la méthode de Vorbrüggen pour la synthèse de 
nucléosides. 
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Mots clés: (+)-Ambruticine S, methyl α-D-glycopyranoside, nucléosides antisens 
[4.3.0]-bicycliques, L-arabinose, allylation de Sakurai, réaction d’aldol intramoléculaire, 
métathèse de fermeture de cycle, glycosylation de Vorbrüggen. 
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Chapter One 
 
Synthesis of Ring A of (+)-Ambruticin S 
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1.1 Introduction 
1.1.1 The Ambruticin Family 
In 1977, researchers at Warner-Lambert reported the isolation of a novel 
antifungal agent, (+)-ambruticin S (1.1a), from fermentation extracts of the 
myxobacterium Polyangium cellulosum var. fulvum.1,2  One year later, this group also 
isolated and characterized  ambruticin F (1.1b),3 which is the 5-epi-isomer of 1.1a, from 
the same fermentation extracts of the myxobacterium.  A series of ambruticin analogues  
(1.1c-h) were later reported in the 1990s by scientists at GBF from a closely related 
myxobacteria strain Sorangium cellulosum Soce10.4  This was known as the VS series, 
bearing an amino group at the C-5 position, and expanded the ambruticin family to 
include these eight members (Table 1.) 5,6   
 
Table 1: The ambruticin family. 
O
OH
R'
RO2C
O
Ambruticin
H
H H
H
R'R
1.1a
1.1b
1.1c
1.1d
1.1e
1.1f
1.1g
1.1h
OHH
α-OH
(NH3)
(NMe3)
H
H
H
H
H
H
Me
S
F
VS-5
VS-4
VS-3
VS-1
VS-3 N-oxide
VS-2
1.1
BA
C
(NOHMe2)
(NH2Me)
(NHMe2)
(NMe3)
1
5
7
11
15 24
 
 
1.1.2 Structure and Biological Activity 
The structure of ambruticin S (1.1a) was elucidated from systematic degradative 
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studies and spectroscopic analysis.  A single crystal X-ray analysis of the triformate ester 
of alcohol 1.3, which was prepared from ambruticin S (1.1a) enabled the determination of 
the relative stereochemistry of the natural product (Scheme 1).1  Further degradation 
studies of ozonolysis fragments of the tetrahydropyran ring A 1.9 and the cyclopropane 
ring 1.10, established the absolute configuration of ambruticin S (Scheme 2).7  The 
natural product features a cis-2,6-tetrasubstituted tetrahydropyran ring (ring A), a 
trisubstituted cyclopropane ring (ring B), a trisubstituted dihydropyran ring (ring C), and 
has a total of 10 stereogenic centers, making it a challenging target for total synthesis. 
 
O
OH
OH
MeO2C
O
H
H H
H
1.2
LiAlH4
THF
CH2N2
EtOH
O
OH
OH
HO2C
O
H
H H
H
1.1a
Ph3P,Br2
DMF
O
OH
OH
O
H
H H
H
1.3
HO O
OCHO
OCHO
O
H
H H
H
1.4
OHCO
BA
C
 
 
Scheme 1: Synthesis of triformate ester (1.4) and X-ray crystal structure.  
(Picture is taken from reference 1) 
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O
OH
OH
HO2C
O
H
H H
H
1.1a
O
OH
OH
MeO2C
O
H
H H
H
1.5
1. O3, -78 oC
2. DMS, Zn(BH4)2
CH2Cl2
O
OH
OH
MeO2C
H H
OH
1.7 1.8
O
OBz
OBz
MeO2C
H H
OBz
1.9 1.10
+ OHHO
BzCl, DMAP,
pyridine
OBzBzO
O
OBz
OBz
MeO2C
O
H
H H
H
1.6
BzCl, DMAP
Et2O
CH2N2
pyridine
BzCl, DMAP,
pyridine
B
A
C
 
 
 
Scheme 2: Degradative study to determine the absolute stereochemistry of ambruticin S.  
 
Biological studies have demonstrated that ambruticin S has low toxicity (LD50 
values for the sodium salt of ambruticin in mice were: intravenous 315 mg/kg, oral > 
1,000 mg/kg) and exhibits potent antifungal activity in vitro and in vivo against a variety 
of biological pathogens.2  The natural product is highly active against Coccidioides 
immitis, Histoplasma capsulatum, and Blastomyces dermatitidis as well as dermatophytic 
filamentous fungi, and demonstrates moderate antibacterial activity against Streptococcus 
pyogenes, with an MIC (Minimum Inhibitory Concentration) of 12.5 µg/mL, Diplococcus 
pneumoniae (MIC 12.5 µg/mL), and Bacillus cereus (MIC 12.5 µg/mL).2  It also shows 
potent activity against Hansenula anomala (MIC 0.03-1.6 µg/mL).2  The ambruticin VS 
series also show low toxicity and antifungal activity.4,8,9 
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1.1.3 Total Synthesis of Ambruticin S - Ring A Strategy 
The unique structural features mentioned above, and the notable biological 
activities of ambruticin S (1.1a) have attracted the attention of many research groups to 
pursue the target for total synthesis.  There have been several methodology based studies 
for constructing the ring A,10,11 ring B,10,12 and ring C13 fragments, and four total 
syntheses of ambruticin S have been reported to date. The first total synthesis of 
ambruticin S was accomplished by Kende and co-workers in 1990.14,15  Three other total 
syntheses have been achieved by Jacobsen16 and Martin17,18 in 2001, followed by Lee19 in 
2002.  Each of these syntheses features a different strategy for the construction of the 
natural product. 
 
1.1.3.1  The Kende Approach     
 In Kende’s retrosynthetic analysis of ambruticin S (1.1a) the natural product 
could be disconnected and simplified to give three separate ring fragments 1.11 (ring A), 
1.12 (ring B), and 1.13 (ring C) using C-glycosidation and Julia olefination 
transformation to link the subunits (Scheme 3). The ring A synthon 1.11 could be 
generated from a protected methyl α-glucopyranoside (1.17)20 by employing 
deoxygenation, Arndt-Eistert homologation,21 and fluorination in the forward direction. 
The cyclopropane 1.12 can be synthesized using Yamamoto dianion chemistry from 
dimenthyl succinate (1.18).22  The side chain of  the ring C precursor 1.13 could be 
installed using an Ireland-Claisen rearrangement strategy, and the dihydropyran ring 
could be assembled via a thermal hetero-Diels-Alder reaction between glyoxylic acid 
(1.20) and (E)-3-methyl-1,3-hexadiene (1.21) followed by a resolution using (+)-α-
 6 
 
methylbenzylamine.  
 
O
OH
OH
HO2C
O
H
H H
H
C-glycosidation Julia olefination
CHO
O F
OBn
OBn
MeO2C O
Ts
H H
(iBu)2Al
+
OHO2C
OBn
OBn
OH
+
Arndt-Eistert
homologation
Ireland-Claisen 
rearrangement
1.1a
1.11 1.12 1.13
1.14
O
OBn
OBn
HO
HO
OH MenO2C CO2Men
CO2MenOHC
Yamamoto dianion
cyclopropanation OH H
AcO
HO O
O
H
+
1.15 1.16
1.17
1.18
1.20 1.21
OHO2C
H H
Hetero-Diels-Alder 
reaction
1.19
BA
C
 
Scheme 3:  Kende’s retrosynthetic analysis of ambruticin S. 
 
1.1.3.2  The Jacobsen Approach 
Jacobsen envisioned that ambruticin S (1.1a) could be simplified to fragments 
1.22 and 1.23 by disconnection of the trans-configured olefin between rings A and B 
(Scheme 4).  The precursor 1.24 for the ring A fragment 1.22 could be generated from 
aldehyde 1.27 and diene 1.28 using an asymmetric hetero-Diels-Alder reaction.  The 
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dihydropyran ring C in 1.26 can be also constructed through an asymmetric hetero-Diels-
Alder strategy involving aldehyde 1.29 and diene 1.30 in conjunction with a suitable 
olefination method, and a Charette cylcopropanation23,24 to furnish the cyclopropane ring 
B. 
 
O
OH
OH
HO2C
O
H
H H
H
Julia-Kocienski olefination
O
OTBS
OTBS
+
Hetero-Diels-Alder 
reaction
CHOTBDPSO
OTBS
BnO
HTBDPSO
O
+
Charette
cyclopropanation
O
H H
SN
N
N N
Ph O O
1.1a
1.22
1.23
1.27 1.28
O
H H
HO
O
H H
TBSO
1.25
1.26
OTES
HTBSO
O
1.29 1.30
O
OTBS
TBDPSO
Hetero-Diels-Alder 
reaction
OBn
1.24
OTES
+
B
A
C
 
Scheme 4: Jacobsen’s retrosynthetic analysis of ambruticin S. 
 
1.1.3.3  The Martin Approach 
Martin’s retrosynthetic analysis of ambruticin S commenced with the 
disconnection the two disubstituted olefins via Julia-Kociensky and Julia olefination 
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transformations to give three subunits 1.31, 1.32, and 1.33 (Scheme 5).  Ring A fragment 
1.31 can be taken back to triol 1.34, whose synthesis could be envisaged through an 
intramolecular Michael addition of the intermediate acetonide 1.37.  Acetonide 1.37 
could be further reduced to the known aldehyde 1.40.25  Ring B subunit 1.32 could be 
simplified to the cyclopropane intermediate 1.35, which could be taken back to the 
lactone 1.38.  Martin anticipated that lactone 1.38 could be prepared via a Doyle 
cylcopropanation reaction from diazoester 1.41.26,27  Ring C fragment 1.33 could be 
retrosynthetically reduced to homoallylic alcohol 1.36, which could be accessed through 
a [2,3]-Wittig rearrangement in the forward direction from allylic alcohol 1.39.  This 
allylic alohol moiety of 1.39 could be made using a chelate controlled Grignard addition 
to a methyl ketone, and the dihydropyran ring could be disconnected using a ring-closing 
metathesis (RCM) reaction, simplifying its synthesis and further reducing to diene 1.42.  
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Scheme 5: Martin’s retrosynthetic analysis of ambruticin S. 
 
1.1.3.4 The Lee Approach 
The key disconnections in Lee’s retrosynthetic analysis of ambruticin S (1.1a) are 
similar to that of Martin’s plan, where scission of the two disubstituted olefins simplifies 
the synthesis to three subunits 1.43, 1.44, and 1.45 (Scheme 6).   The ring A aldehyde 
subunit 1.43 could be retrosynthetically reduced to intermediate 1.46 by employing a 
 10 
 
radical cyclization.  Furthermore, 1.46 could be traced back to commercially available L-
arabinose (1.53).  The ring B cyclopropane subunit 1.44 could be brought back to 
intermediate 1.47, and the synthesis of this cyclopropane can be envisaged via 
Yamamoto’s dianion chemisty to give 1.50,22 which mirrors the Kende approach to this 
ring B fragment.  Ring C subunit 1.45 could be taken back to ketone 1.48, which could be 
further reduced to Grignard reagent 1.51 and oxazolidinone 1.52.  From here, it was 
envisaged that the dihydropyran ring could be disconnected via a RCM reaction to 
furnish the diene 1.54, which could ultimately be brought back to the chiral allylic 
alcohol 1.55. 
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Scheme 6: Lee’s retrosynthetic analysis of ambruticin S. 
 
1.1.4 Retrosynthetic Analysis of Ambruticin S – the Ring A Strategy 
The retrosynthetic analysis outlined in Scheme 7 along with the synthetic details 
discussed below, are new results discovered during the course of this dissertation.  It was 
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envisioned that ambruticin S could be disconnected to furnish three subunits, which could 
be assembled in the forward sense using a phosphonamide anion based olefination and a 
C-glycosidation reaction respectively.  The lactone 1.56, which is readily available from 
methyl α-D-glucopyranoside (1.65), contains three of the stereogenic centers present in 
ring A of ambruticin S.  Use of 1.65 as a starting material in the synthesis of the ring A 
subunit of ambruticin S will require deoxygenation at C-4 and a one carbon homologation 
of the C-6 side chain.  The trisubstituted cyclopropane subunit 1.57 could be simplified to 
compounds 1.61 and 1.62, which could be coupled in the forward direction using 
phosphonamide anion chemistry developed in the Hanessian laboratory to construct both 
the olefin28 and cyclopropane ring29,30,31 in 1.57.  The C-methyl stereogenic center of the 
acyclic chain of ambruticin S would come from the (R)-Roche ester (1.62).  Synthesis of 
the ring C subunit of ambruticin S would employ a highly diastereoselective Lewis acid 
catalyzed 6-endo-trig cyclization32 also developed in the Hanessian laboratory.  The third 
and final subunit, diol 1.58, would be provided from a dithiane anion addition to (R)-
glycidol benzyl ether (1.63).  For the synthesis of ring A, two possible routes that 
involved the use of 1.65 were envisaged.   
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Scheme 7:  Retrosynthetic analysis of ambruticin S. 
 
1.2 Results and Discussion 
1.2.1 Synthesis of Ring A Lactone 1.54 - Route I 
Modification of Guiliano and Buzby’s procedure,33 enabled the synthesis of 
aldehyde 1.71 in six steps and 55% overall yield (Scheme 8).  Starting from the 
commercial available methyl 4,6-O-benzylidene α-D-glucopyranoside (1.64), the diol 
was protected as bis-benzyl ether 1.66.  Removal of the benzylidene acetal upon 
treatment with TsOH in ethanol, gave the diol 1.67.  Selective protection of the primary 
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alcohol as the trityl ether, followed by mesylation of the secondary alcohol furnished 1.69 
in 71% yield over two steps.  Acid cleavage of the trityl ether gave primary alcohol 1.70 
in near quantitative yield.  Oxidation of 1.70 under Parikh-Doering conditions was 
accompanied by elimination of the methanesulfonate group to give the α,β-unsaturated 
aldehyde 1.71 in 97% yield.  Catalytic hydrogenation of 1.71 by using Pd/BaCO3 as a 
catalyst, and subsequent epimerization in the presence of DBU, afforded 1.72.   The one 
carbon homologation of the C-6 appendage was achieved upon treatment of aldehyde 
1.72 with the ylide generated from methyl triphenylphosphonium bromide to give vinyl 
tetrahydropyran 1.73.  Hydroboration of the olefin with 9-BBN and oxidation produced 
the primary alcohol 1.74 in 90% yield.  After protection of the free hydroxyl group as the 
benzyl ether, hydrolysis of the methyl glycoside under acidic conditions, and subsequent 
PCC oxidation of the lactol gave the desired lactone 1.56 in 57% yield over three steps.  
Thus, the synthesis of 1.56 was accomplished in 12 steps from commercially available 
and inexpensive methyl 4,6-O-benzylidene α-D-glucopyranoside (1.64) in 18% overall 
yield.  
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Scheme 8: Route I for the synthesis of ring A lactone 
 
1.2.2 Route II for the Synthesis of the Ring A Lactone  
Treatment of methyl α-D-glucopyranoside (1.65) with sulfuryl chloride in the 
presence of pyridine, followed by hydrolysis with sodium iodide in aqueous methanol, 
afforded 1.77 in 86% yield34,35 (Scheme 9).  Chemoselective dehalogenation of the 
secondary chloride in 1.77 was achieved using hydrogen gas in the presence of Raney 
nickel to furnish the  diol 1.78,36 which was converted to the bis-benzyl ether 1.79 in 67% 
yield over two steps.  Displacement of the primary chloride in 1.79 with NaCN was 
sluggish and resulted in only 37% yield (with recovery of 41% of the starting material) 
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for the homologated nitrile 1.80.37 Using different solvents, like DMSO, DMF, HMPA, 
and using KCN instead of NaCN, with different equivalents, all gave low yields. 
Nevertheless, reduction with DIBAL-H to the aldehyde, followed by treatment with 
NaBH4 gave the intermediate primary alcohol 1.72 in 67% yield over two steps.  
Application of the identical three step sequence described in Scheme 8 furnished 1.56. 
The synthesis of 1.56 was accomplished in 10 steps from methyl α-D-glucopyranoside 
(1.65) in 15% overall yield.  
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O OMe
OBn
OBn
HO
67%37%
86% 70% 96%
1.65 1.77 1.78
1.79 1.80 1.74  
Scheme 9: Route II for the synthesis of intermediate 1.74  
 
1.2.3 Route III for the Synthesis of the Ring A Lactone  
A third route (Route III) to the lactone 1.74 (Scheme 10), which started from 
intermediate 1.79, was also devised during the course of the total synthesis of ambruticin 
S.  The four-step route involved a radical-mediated allylation reaction of 1.79 to afford 
1.81, which was subsequently subjected to an olefin isomerization reaction using Grubbs’ 
second generation catalyst according to a method reported by Hanessian and co-
workers.38  Dihydroxylation of the olefin, and oxidative cleavage of the resulting diol, 
followed by NaBH4 reduction of the aldehyde gave intermediate alcohol 1.74 in seven 
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steps and 16% overall yield.  
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 Scheme 10: Route III for the synthesis of intermediate 1.74  
 
1.2.4 Discussion for the Synthesis of Ring A 
Comparing all three routes for the synthesis of ring A of ambruticin S in Table 2, 
Route I gave the highest yield even though it required 12 steps from methyl 4,6-O-
benzylidene α-D-glucopyranoside (1.64). Route II was achieved in 9% overall yield over 
nine steps due to the modest yield (37%) of homologation step. Route III used a 
homologation and isomerization in the presence of Grubbs’ second generation catalyst 
strategy developed in Hanessian group38 furnished the ring A lactone in 10 steps and 12% 
yield. In all these approaches, Route I was the highest yielding and avoided using the 
highly toxic organostannane and was thus considered as the most practical and efficient 
way to access the desired ring A lactone. 
 
Kende,11,12 Martin,13,14 and Lee15 all start from carbohydrate derivatives, which 
possessed the diol with the required stereochemistry on ring A. Jacobsen16 utilized a 
catalytic asymmetric hetero-Diels-Alder reaction to rapidly construct the ring A 
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framework and finally achieved the shortest synthesis of ambruticin S.  
 
Table 2. Comparison of the three routes for ring A synthesis 
 
 
Start material 
 
To intermediate 
1.74 
 
To lactone 
1.56 
Route I 
 
9 steps, 
32% yield. 
12 steps, 
19% yield. 
Route II 
 
6 steps, 
14% yield. 
9 steps, 
8% yield. 
Route III 
 
 
7 steps, 
21% yield. 
 
 
10 steps, 
12% yield. 
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Table 3. Comparison of ring A syntheses in previous total syntheses  
 Start material Ring A synthons 
Kende 
 
 
26% yield, 9 steps 
Jacobsen 
 
OTBS
BnO
HTBDPSO
O +
O
Cr
N
Cl
O
cat.  
 
53% yield, 5 steps 
Martin 
 
 
46% yield, 5 steps 
Lee 
 
 
25% yield, 11 steps 
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1.2.5 Synthesis of Ring C 
The construction of ring C of ambruticin S was accomplished by other members 
of our group (Scheme 11).6 It started from (R)-glycidol benzyl ether (1.63) and dithiane 
1.83.39 Deprotonation of the E-dithiane with butyllithium and treatment of the resulting 
anion with epoxide 1.63 afforded intermediate 1.84 in 97%.  Protection of the secondary 
hydroxyl group in 1.84 as the TBS ether proved to be essential in order to successfully 
cleave the dithiane moiety and unmask the α,β-unsaturated system. Cleavage of the 
dithiane was achieved in the presence of benzeneseleninic acid anhydride to give the 
relatively unstable enone 1.85 in 60% overall yield.40  Luche reduction, followed by TBS 
deprotection with TBAF furnished diol 1.58 as a 3.6:1 mixture of diastereomers. 
Treatment of the diol with a catalytic amount of BF3·OEt2 proceeded smoothly via 6-
endo-trig cyclization to furnish the desired dihydropyran 1.86 in 81% yield on a multi-
gram scale.32  The benzyl group was then removed under Birch conditions to give alcohol 
1.87 in 88% yield.  Swern Oxidation, followed by addition of a methyl Grignard reagent 
to the resulting aldehyde gave a secondary alcohol which was then oxidized again under 
Swern conditions to furnish desired ketone 1.88 in 72% yield over three steps.13 
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Scheme 11: Synthesis of ring C  
 
1.2.6 Synthesis of Ring B  
Synthesis of the cyclopropane unit, and ring B of ambruticin S was achieved by 
other members of our group (Scheme 12).6 Thus, deprotonation of trans-chloro-allyl 
phosphonamide 1.6129 with n-butyllithium at low temperature, followed by addition of 
tert-butyl crotonate (1.89) afforded the desired cyclopropane 1.90 as a single 
diastereomer in 89% yield.  The phosphonamide chiral auxiliary was cleaved upon 
ozonolysis of 1.90 to give the crystalline aldehyde 1.91 in 70% yield.6 
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Scheme 12: Synthesis of ring B 
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1.2.7 Synthesis of Ring B and Ring C Union Fragment 1.100 
With the ring C dihydropyran 1.88 and the ring B cyclopropane 1.91 in hand, two 
approaches were developed to achieve the union fragment 1.100.6 The first approach was 
realized in a linear fashion starting from dihydropyran 1.88 (Scheme 13). Thus, 1.88 was 
reacted with phosphonamide 1.94, which is derived from alkylation of 1,3-dimethyl-2-
oxo-1,3,2-diazaphospholidine (1.93) with (R)-3-tert-butyldimethylsilyloxy-2-
methylpropyl iodide (1.92).41,42 Deprotonation of 1.94 at low temperature followed by 
addition of ketone 1.88 and quenching with AcOH afforded a separable 6:1 mixture of 
E/Z isomers, with the desired compound as the major one.32 Then cleavage of the TBS 
ether with TBAF gave alcohol 1.95 in 58% yield (two steps). The alcohol 1.95 was then 
converted into the corresponding iodide in the presence of iodine and PPh3, followed by 
displacement of the iodide with the anion of phosphorous acid diamide 1.93 to give 
phosphonamide 1.97 (76% yield, two steps). Olefination of cyclopropyl aldehyde 1.91 
with the lithium anion of 1.97 proceeded with excellent selectivity (E/Z>25:1) to give 
diene 1.98. Reduction of the tert-butyl ester by DIBAL-H gave alcohol 1.99 in 96% 
yield, followed by Swern oxidation to the corresponding aldehyde, and treatment with the 
Ohira-Bestmann reagent43,44  then provided alkyne 1.100 in 82% over the final two steps. 
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Scheme 13: Synthesis of ring B and ring C union fragment 1.100, first approach 
 
In a second approach to 1.100 (Scheme 14), reaction of the crystalline aldehyde 
1.91 with the anion prepared from phosphonamide ent-1.94 afforded 1.101 with excellent 
E/Z selectivity (>25:1).  DIBAL-H reduction of ester 1.101 to an alcohol, then Swern 
oxidation gave aldehyde 1.100 in 83% yield (two steps). Treatment of 1.102 with the 
Ohira-Bestmann reagent affored homologation product alkyne 1.103 (71% overall yield). 
The alkyne moiety in 1.103 was then transformed to its TIPS derivative 1.104, followed 
by selective cleavage of the silyl ether. Treatment of the resulting alcohol with iodine and 
PPh3 gave iodide 1.105. The iodide was the converted to 1.57 in 79% yield in the 
presence of the lithium anion of 1,3-dimethyl-2-oxo-1,3,2-diazaphospholidine (1.93) at 
low temperature. Phosphonamide 1.57 was then deprotonated with n-butyllithium, and 
coupled with ketone 1.88 to give 1.106 as a separable 6:1 mixture of E/Z isomers in 45% 
yield, with the desired E-olefin as major isomer. Finally, treatment of 1.106 with TBAF 
furnished alkyne 1.100 in 88% yield. 
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Scheme 14: Synthesis of ring B and ring C union fragment 1.100, second approach 
 
Comparing these two approaches to fragment 1.100, the first one (Scheme 13) 
commenced from the ring C ketone 1.88, and used sequential phosphonamide anion 
olefinations to successfully furnish the ring B and ring C containing fragment 1.100. The 
second approach resulted in a more convergent synthesis of alkyne 1.100, and used a 
reverse sequence, starting from the ring B aldehyde 1.91. It also employed the reliable 
phosphonamide anion methodology to produce the trans-olefins with good selectivity 
(E/Z >25:1 for 1.101; E/Z >6:1 for 1.106). 
 
1.2.8 Completion of Synthesis of (+)-Ambruticin S (1.1a) 
With alkyne 1.100 and the lactone 1.56 in hand now, the final synthesis of (+)-
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ambruticin S (1.1a) was accomplished by Dr. Thilo Focken in our group (Scheme 15).6 
Deprotonation of 1.100 with n-butyllithium, followed by addition of lactone 1.56, led to a 
1:1 diastereomeric mixture of the desired products. The anomeric hydroxyl group of the 
intermidiate was then removed by treatment with triethylsilane and BF3·OEt2 at low 
temperature45 and afforded C-glycoside 1.107 in 66% yield as a single diastereomer with 
the desired syn-stereochemistry of the newly formed tetrahydropyran. Selective removal 
of the benzyl groups in the presence of lithium 4,4-di-tert-butylbiphenylide (LiDBB)46 
provided alkyne 1.108 in 89% yield. Reduction of alkyne 1.108 with sodium bis(2-
methoxyethoxy) aluminum hydride (Red-Al) in diethyl ether furnished the known16 
trans-triol 1.109 (80% yield, E/Z>10:1). Final oxidation of the primary hydroxyl group of 
triol 1.109 in the presence of the two secondary hydroxyls was accomplished using a 
method already employed by Liu and Jacobsen.16 Thus, platinum-catalyzed oxidation of 
1.109 with oxygen in aqueous solution at 50 ºC provided (+)-ambruticin S (1.1a) in 91% 
yield. The spectral data (1H and 13C NMR) of synthetic (+)-ambruticin S (1.1a) thus 
obtained were identical with those reported for the natural product. The absolute 
configuration was also confirmed from an X-ray analysis of the crystal structure of the 
triformate ester 1.110 corresponding to the reduced triol 1.109 (Scheme 16).6 
 
 
 26 
 
1. 1.56, n-BuLi
    THF, -78 ºC
64%
O
OBn
OBn
BnO
OH H
H H
2. BF3·OEt2, Et3SiH
    CH3CN, CH2Cl2
    -40 ºC
Pt, O2
H2O, i-PrOH
Me2CO, 50 ºC
80%
 E/Z > 10:1
91%
O
OH
OH
HO
OH HRed-Al
89%
HH
LiDBB 
THF, -78 ºC
Et2O, 0 ºC
1.1a
O
OH
OH
HO2C
O
H H
HH
OH H
H
1.100
O
OH
OH
HO
OH H
H H
1.107
1.108 1.109
 
Scheme 15: Completion of synthesis of (+)-ambruticin S (1.1a) 
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Scheme 16: ORTEP drawing of X-ray crystal structure of triformate ester 1.110 
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1.2.9 Discussion 
In our strategy for the synthesis of ring A, we started from commercially available 
and inexpensive methyl α-D-glucopyranoside (1.65), and taking advantage of inherent 
resident chirality, we developed three practical routes for the synthesis of the ring A 
lactone. In conjunction with other efforts in our group, we then successfully synthesized 
ambruticin S (1.1a). A highly steroselective cyclopropanation(1.61→1.90; Scheme 12) 
(89%, dr 99:1) led to the efficient construction of the B ring in only two steps. For the 
synthesis of ring C, a 6-endo-trig Lewis acid mediated cycloetherification was used 
which was adaptable to the synthesis of a variety of substituted analogues.  
 
In summary, we have accomplished highly enantioselective total synthesis of (+)-
ambruticin S (1.1a) in 17 steps and 5% overall yield (15% based on recovered starting 
material) in the longest linear sequence starting from glycidol 1.63. Our approach for the 
total synthesis of (+)-ambruticin S (1.1a) provides a convenient way to a variety of 
ambruticin derivatives.6  
 
1.3 Experimental Procedures 
General information: All non-aqueous reactions were run in flame-dried glassware 
under a positive pressure of argon. Anhydrous solvents were distilled under positive 
pressure of dry argon before use and dried by standard methods. THF, ether, DCM and 
toluene were dried by the SDS (Solvent Delivery System), commercial grade reagents 
were used without further purification. Reactions were monitored by S-2 analytical thin-
layer chromatography (TLC) performed on pre-coated, glass-backed silica gel plates. 
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Visualization of the developed chromatogram was performed by UV absorbance (wave 
length: 254 nm), and staining TLC plates with aqueous cerium ammonium molybdate, 
iodine, or aqueous potassium permanganate solution. Flash chromatography was 
performed on 230-400 mesh silica gel with the indicated solvent systems. Melting points 
were recorded on BÜCHI Melting Point B-540. Infrared spectra were recorded on a 
Perkin-Elmer FTIR Paragon 1000 and were reported in reciprocal centimeters (cm-1). 
Nuclear magnetic resonance spectra (NMR) were recorded either on Bruker AV-300 
MHz and AV-400 MHz spectrometers. Chemical shifts for 1H NMR spectra are recorded 
in parts per million from tetramethylsilane with the solvent resonance as the internal 
standard (CDCl3 δ 7.27 ppm). Data are reported as follows: chemical shift, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, qn = quintet, m = multiplet, and br = broad), 
coupling constants were reported Hz, and integration. Chemical shifts for 13C NMR 
spectra are recorded in parts per million from tetramethylsilane using the central peak of 
the solvent resonance as the internal standard (CDCl3, δ 77.00 ppm). All spectra were 
obtained with complete proton decoupling. Optical rotations were determined in a 1 dm 
cell at 589 nm at 20 ºC (Perkin Elmer 343). Data are reported as follows: [α]D, 
concentration (c in g/100 mL), and solvent. High-resolution mass spectra were performed 
using fast atom bombardment (FAB) or electrospray (ESI) techniques. Low-resolution 
mass spectra were obtained using electrospray ionisation technique (ESI). 
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Methyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (1.66): Sodium 
hydride (1.72 g, 43.0 mmol) as a 60% dispersion in mineral oil was added to a stirred 0ºC 
DMF (90 mL) solution of 1.64 (5.0g, 17.2 mmol) and benzyl bromide (10.45 mL, 43.0 
mmol). The resulting suspension was allowed to warm up to room temperature and 
stirred overnight. The reaction mixture was then diluted with ether (50 mL), followed by 
the addition of a saturated solution of NH4Cl (25 mL). The organic layer was separated, 
washed with a saturated NH4Cl solution (50 mL), brine (50 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography (hexanes/EtOAc, 10:1 to 4:1) to give the product 1.66 as a white solid 
(7.55 g, 95%), mp 90-93 ºC, (hexanes/EtOAc), lit.47 95.5-96 ºC. 1H NMR (400 MHz, 
CDCl3) δ 7.48-7.24 (m, 15H), 5.55 (s 1H), 4.90 (d, J = 14.8 Hz, 1H), 4.84 (d, J = 12.0 
Hz, 1H), 4.81 (d, J = 15.2 Hz, 1H), 4.68 (d, J = 16.4 Hz, 1H), 4.57 (d, J = 4.8 Hz, 1H), 
4.25 (dd, J = 13.2, 6.0 Hz, 1H), 4.03 (d, J = 12.4 Hz, 1H), 3.82-3.77 (m, 1H), 3.68 (t, J = 
13.6 Hz, 1H), 3.58 (t, J = 12.4 Hz, 1H), 3.54 (dd, J = 12.4, 4.8 Hz, 1H), 3.38 (s, 3H). 13C 
NMR (100MHz, CDCl3) δ 138.6, 138.1, 137.3, 128.8, 128.4, 128.2, 128.1, 128.0, 127.9, 
127.8, 127.5, 125.9, 101.2, 99.1, 82.0, 79.0, 78.5, 75.3, 73.7, 69.0, 62.2, 55.3 IR (film, 
NaCl) 3064, 3032, 2917, 2867, 1497, 1452, 1368, 1328, 1212, 1176, 1109, 1088, 1052, 
1028, 1001, 921, 738, 695 cm-1. [α]D: (–) 26.8° (c 1.02, CHCl3), lit.47 [α]D: (–) 30.9° (c 
2.0, CHCl3). LRMS (ESI) calcd for C28H31O6 (M+H)+ 463.2, found 463.2. 
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Methyl 2,3-di-O-benzyl-α-D-glucopyranoside (1.67): p-Toluenesulfonic acid 
monohydrate (44 mg, 0.23 mmol) was added to a stirred ethanol (140 mL) solution of 
dibenzyl ether methyl 2,3-di-O-benzyl-α-D-gycopyranoside 1.66 (8.29 g, 17.9 mmol) at 
room temperature. The resulting mixture then was heated and refluxed for 18 hours. After 
cooling to room temperature, the mixture was diluted with chloroform (100 mL) and 
washed with a saturated solution of NaHCO3 (50 mL), water (50 mL), and brine (50 mL). 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure to afford a colorless syrup. Colorless crystals 1.67 (5.73 g, 86%) were obtained 
upon treatment with (hexanes/EtOAc, 10:1), mp 76-78 ºC, (hexanes/EtOAc), lit.33 78-79 
ºC, (petroleum ether/EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.38-7.30 (m, 10H), 5.02 (d, 
J = 11.2 Hz, 1H), 4.77 (d, J = 12 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.66 (d, J = 12 Hz, 
1H), 4.60 (d, J = 3.6 Hz, 1H), 3.82-3.72 (m, 3H), 3.63-3.59 (m, 1H), 3.55-3.48 (m, 2H), 
3.38 (s, 3H). 13C NMR (100MHz, CDCl3) δ 138.6, 137.9, 128.5, 128.4, 128.0, 127.9, 
98.1, 81.2, 79.7, 75.3, 73.0, 70.6, 70.3, 62.3, 55.2 IR (film, NaCl) 3430, 3063, 3030, 
2917, 1496, 1454, 1360, 1155, 1091, 1053, 1028, 909, 737, 697 cm-1. [α]D: (+) 14.0° (c 
1.40, CHCl3), lit.33 [α]D: (+) 16.5° (c 0.279, CHCl3). LRMS (ESI) calcd for C21H26NaO6 
(M+Na)+ 397.2, found 397.1. 
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Methyl 2,3-di-O-benzyl-6-O-triphenylmethyl-α-D-glucopyranoside (1.68): 
Triphenylmethyl chloride (4.68 g, 16.8 mmol) was added to a 0 ºC dichloromethane (30 
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mL) solution of 1.67 (5.73 g, 15.3 mmol), followed by addition of triethylamine (3.2 mL 
23.0 mmol), and a catalytic amount of N,N-dimethylaminopyridine. The reaction mixture 
was stirred overnight at room temperature, then quenched with a saturated solution of 
NH4Cl (10 mL). After phase separation, the aqueous layer was extracted with EtOAc (50 
mL) three times. The combined organic phase was washed with water (50 mL), brine (50 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatograpy (hexanes/EtOAc, 10:1) to give 1.68 as a light yellow 
viscous syrup (7.85g, 98%). 1H NMR (400 MHz, CDCl3) δ 7.52-7.25 (m, 25H), 5.03 (d, J 
= 11.6 Hz, 1H), 4.85-4.80 (m, 2H), 4.75-4.72 (m, 2H), 3.84 (t, J = 9.2 Hz, 1H), 3.79-3.75 
(m, 1H), 3.63-3.57 (m, 2H), 3.48 (S, 3H), 3.42 (dd, J = 10.0, 3.6 Hz, 1H), 3.35 (dd, J = 
10.0, 5.6 Hz, 1H). 13C NMR (100MHz, CDCl3) δ 143.7, 138.7, 138.1, 128.6, 128.4, 
127.9, 127.7, 126.9, 97.9, 86.7, 81.5, 79.6, 75.5, 73.0, 71.5, 69.9, 63.8, 55.0. [α]D: (+) 
13.0° (c 0.16, CHCl3), lit.33 [α]D: (+) 4.66° (c 0.3, CHCl3). LRMS (ESI) calcd for 
C40H40NaO6 (M+Na)+ 639.3, found 639.3. 
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Methyl 2,3-di-O-benzyl-4-O-methanesulfonyl-6-O-triphenylmethyl-α-D- 
glucopyranoside (1.69): A solution of methanesulfonyl chloride (3.00 mL, 38.65 mmol) 
in chloroform (25 mL) was added slowly to a 0 ºC pyridine (100 mL) solution of 1.68 
(6.99 g, 11.3 mmol). The reaction mixture was stirred overnight at room temperature, 
then poured into water (50 mL) and extracted with diethyl ether (50 mL) three times. The 
 32 
 
combined organic phase was washed with 5% aqueous HCl solution (100 mL), saturated 
solution of NaHCO3 (100 mL), water (50 mL), and brine (50 mL), then dried over 
Na2SO4, filtered and concentrated under reduce pressure. The residue was purified by 
flash chromatograpy (hexanes/EtOAc, 10:1) to give 1.69 as amorphous solid (6.74g, 
86%). 1H NMR (400 MHz, CDCl3) δ 7.51-7.24 (m, 25H), 5.00 (d, J = 10.4 Hz, 1H), 
4.84-4.69 (m, 4H), 4.48 (t, J = 9.6 Hz, 1H), 3.98-3.94 (m, 2H), 3.66 (dd, J = 9.6, 3.6 Hz, 
1H), 3.56 (s, 3H), 3.48 (dd, J = 10.8, 2.0 Hz, 1H), 3.31 (dd, J = 10.4, 6.8 Hz, 1H), 2.55 (s, 
3H). 13C NMR (100MHz, CDCl3) δ 143.5, 137.8, 137.6, 128.7, 128.4, 128.3, 128.0, 
127.7, 127.0, 97.4, 86.7, 80.1, 78.9, 78.0, 75.6, 73.3, 68.7, 62.7, 55.2, 38.4. [α]D: (+) 
24.60° (c 0.20, CHCl3), lit.33 [α]D: (+) 20.0° (c 0.195, CHCl3). LRMS (ESI) calcd for 
C41H42NaO8S (M+Na)+ 717.2, found 717.2. 
 
O
OMe
OBnBnO
HO
MsO
O
OMe
OBnBnO
TrO
MsO TsOH
EtOH
98%
1.69 1.70  
 
Methyl 2,3-di-O-benzyl-4-O-methanesulfonyl-α-D-glucopyranoside (1.70): p-
Toluenesulfonic acid (72 mg, 0.38mmol) was added to a ethanol (200 mL) solution of 
1.69 (6.74 g, 9.71 mmol). The resulting mixture was heated to reflux overnight. The 
reaction mixture was diluted with chloroform (100 mL), washed with a saturated solution 
of NaHCO3 (100 mL), water (100 mL), and brine (100 mL). The organic phase was dried 
over Na2SO4, filtered and concentrated under reduce pressure. The residue was purified 
by flash chromatograpy (hexanes/EtOAc, 2:1) to give 1.70 as a colorless oil (4.31g, 
98%). 1H NMR (400 MHz, CDCl3) δ 7.36-7.28 (m, 10H), 5.12-5.07 (d, J = 12.8 Hz, 1H), 
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4.75 (d, J = 12.0 Hz, 2H), 4.69-4-62 (d, J = 11.2 Hz, 2H), 4.48 (t, J = 9.6 Hz, 1H), 4.05 (t, 
J = 9.6 Hz, 1H), 3.92 (dd, J = 12.8, 3.2 Hz, 1H), 3.78 (dd, J = 13.2, 2.0 Hz, 1H), 3.73 (dt, 
J = 10.0, 2.4 Hz, 1H), 3.60 (dd, J = 9.6, 3.6 Hz, 1H), 3.39 (s, 3H), 2.80 (s, 3H). 13C NMR 
(100MHz, CDCl3) δ 137.7, 137.3, 128.5, 128.4, 128.1, 127.8, 127.6, 97.6, 80.0, 78.4, 
77.5, 75.6, 73.2, 69.5, 60.2, 55.4, 38.1. [α]D: (+) 36.1° (c 0.24, CHCl3), lit.33 [α]D: (+) 
40.9° (c 0.235, CHCl3). LRMS (ESI) calcd for C22H28NaO8S (M+Na)+ 475.1, found 
475.1. 
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Methyl 2,3-di-O-benzyl-4-deoxy-β-L-threo-hex-4-ene-dialdopyranoside (1.71): A 
solution of triethylamine (66 mL, 475 mmol) and sulfur trioxide pyridine complex (13.6 
g, 85.5 mmol) in dimethylsulfoxide (38 mL) was added dropwise to a 0 ºC 
dichloromethane (75 mL) solution of 1.70 (4.30 g, 9.5 mmol). After 15 min the reaction 
mixture was allowed to warm to room temperature and stirred for three hours. 
Subsequently, the mixture was partitioned between CH2Cl2 (50 mL) and water (50 mL). 
The organic phase was washed with 1 N HCl (50 mL), saturated solution of NaHCO3 (50 
mL), water (50 mL), and brine (50 mL), then dried over Na2SO4, filtered and 
concentrated under reduce pressure. The residue was purified by flash chromatograpy 
(hexanes/EtOAc, 5:1) to give 1.71 as a yellowish, viscous syrup (3.29g, 97%). 1H NMR 
(400 MHz, CDCl3) δ 9.20 (s, 1H), 7.39-7.32 (m, 10H), 5.89 (d, J = 2.8 Hz, 1H), 4.96 (d, J 
= 2.4 Hz, 1H), 4.84 (d, J = 12.4 Hz, 1H), 4.79 (d, J = 12.2 Hz, 2H), 4.74 (d, J = 11.6 Hz, 
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2H), 4.51 (dd, J = 8.0, 2.8 Hz, 1H), 3.83 (dd, J = 8.0, 2.4 Hz, 1H), 3.48 (s, 3H). 13C NMR 
(100MHz, CDCl3) δ 185.9, 148.2, 137.7, 137.6, 128.4, 128.0, 127.9, 127.8, 127.7, 120.4, 
99.6, 76.2, 73.3, 73.1, 72.4, 56.8. [α]D: (+) 179.9° (c 0.68, CHCl3), lit.33 [α]D: (+) 147.7° 
(c 0.627, CHCl3). LRMS (ESI) calcd for C21H26NO5 (M+NH4)+ 372.2, found 372.1. 
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Methyl 2,3-di-O-benzyl-4-deoxy-α-D-xylo-hexodialdopyranoside (1.72). 5% palladium 
on barium carbonate (540 mg) was added to a methanol (16 mL) solution of 1.71 (500 
mg, 1.41 mmol). The resulting mixture was stirred under an atmosphere of hydrogen 
(14.5 psi) for 12 hours. Palladium was then removed by filteration through a pad of 
Celite, the filtrate was concentrated under reduced pressure to a volume of approximately 
8 mL, and 1,8-diazabicycloundec-7-ene (1.2 mL, 8.5 mmol) was added to it. The reaction 
mixture was stirred for additional 12 hours. Then it was concentrated to dryness under 
reduced pressure. The residue was dissolved in dichloromethane (25 mL), washed with 2 
M aqueous HCl solution (10 mL), saturated solution of NaHCO3 (10 mL), and brine (25 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (hexanes/EtOAc, 4:1 to 3:1) to give 1.72 as a 
colorless oil. (432 mg, 86%). 1H NMR (400 MHz, CDCl3) δ 9.62 (s, 1H), 7.34-7.29 (m, 
10 H), 4.87 (d, J = 12.4 Hz, 1H), 4.77-4.74 (m, 3H), 4.69 (d, J = 2.0 Hz, 1H), 4.18 (dd, J 
= 12.4, 2.8 Hz, 1H), 3.98 (ddd, J = 10.8, 9.2, 5.2 Hz, 1H), 3.48 (dd, J = 9.2, 3.2 Hz, 1H), 
3.41 (s, 3H), 2.36 (ddd, J = 13.2, 5.2, 2.8 Hz, 1H), 1.48 (q, J = 12.4 Hz, 1H); 13C NMR 
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(100 MHz, CDCl3) δ 199.5, 138.3, 138.1, 128.3, 128.2, 127.9, 127.8, 127.7, 127.6,  
127.5, 99.3, 79.7, 74.5, 73.5, 72.4, 72.2, 55.6, 31.6; [α]D: (+) 35.0° (c 1.05, CHCl3), lit.33 
[α]D: (+) 23.2° (c 2.95, CHCl3).  LRMS (ESI) calcd for C21H25O5 (M+H)+ 357.2, found 
357.1. 
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Methyl 6-C-vinyl-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside (1.73). n-BuLi 
(10.5 mL of a 1.6M solution in hexanes, 16.9 mmol) was added slowly to a stirred 
suspension of methyltriphenylphosphonium bromide (6.0 g, 16.9 mmol) in THF (60 mL) 
at -78 ºC. After 10 min, the resulting solution was allowed to warm to 0 ºC and stirred for 
1 hour. A solution of 1.72 (2.0 g, 5.6 mmol) in THF (60 mL) was then added slowly to 
the ylide at 0 ºC. The reaction mixture was allowed to warm to temperature, stirred 
overnight, and subsequently quenched by addition of saturated NH4Cl solution (10 mL). 
After extraction of the aqueous layer with diethyl ether (50 mL) three times, the 
combined organic phase was washed with water (50 mL), brine (50 mL), dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography (hexanes/EtOAc, 10:1 to 8:1) to give 1.73 as a colorless oil, (1.51 
g, 76%). 1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 10H), 5.82 (ddd, J = 17.6, 9.6, 6.0 
Hz, 1H), 5.76 (dt, J = 17.2, 1.6 Hz, 1H), 5.14 (dt, J = 10.4, 1.2 Hz, 1H), 4.86 (d, J = 12.0 
Hz, 1H), 4.78 (d, J = 12.4 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 
 36 
 
4.69 (d, J = 3.6 Hz, 1H), 4.21 (dd, J = 11.6, 5.6 Hz, 1H), 3.97 (ddd, J = 11.2, 9.2, 4.8 Hz, 
1H), 3.49 (dd, J = 5.6, 3.6 Hz, 1H), 3.39 (s, 3H), 2.14 (ddd, J = 12.8, 4.8, 2.0 Hz, 1H), 
1.49 (q, J = 12.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 138.7, 138.4, 138.3, 128.2, 
127.9, 127.6, 128.5, 127.4, 115.7, 99.0, 80.3, 75.1, 73.2, 72.4, 67.6, 55.1, 37.1; [α]D: (+) 
34.1° (c 0.50, CHCl3); IR (film, NaCl) 3063, 3030, 2922, 2854, 1683, 1650, 1604, 1496, 
1454, 1358, 1259, 1192, 1099, 1044, 924, 813, 733, 696 cm-1; HRMS (ESI) calcd for 
C22H26NaO4 (M+Na)+ 377.1723, found 377.1722. 
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Methyl 6-C-(hydroxymethyl)-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside 
(1.74). 9-BBN (24.6 mL of a 0.5 M solution in THF, 12.3 mmol) was added to a THF (10 
mL) solution of 1.73 (545 mg, 1.54 mmol). The reaction mixture was stirred overnight at 
room temperature. Hydrogen peroxide (3.2 mL of a 30% aqueous solution, 30.8 mmol) 
and 3 M NaOH solution (5.1 mL, 15.4 mmol) were then added, and the resulting mixture 
was heated for 2 hours at 55 ºC. After phase separation, the aqueous phase was extracted 
with EtOAc (25 mL) three times. The combined organic phase was washed with water 
(25 mL), brine (25 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (hexanes: EtOAc, 2:1) to 
give 1.74 as a colorless oil, (516 mg, 90%). 1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
10H), 4.86 (d, J = 12.0 Hz, 1H), 4.78 (d, J = 11.6 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.70 
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(d, J = 12.0 Hz, 1H), 4.66 (d, J = 2.4 Hz, 1H), 4.00-3.91 (m, 2H), 3.79-3.76 (m, 2H), 3.48 
(dd, J = 9.6, 3.2 Hz, 1H), 3.38 (s, 3H), 2.07 (ddd, J = 12.8, 4.8, 2.0 Hz, 1H), 1.78-1.72 
(m, 2H), 1.48 (q, J = 12.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 138.5, 138.1, 128.0, 
128.0, 127.6, 127.4, 127.3, 127.1, 98.6, 80.1, 74.8, 73.0, 72.2, 66.7, 60.5, 54.8, 37.7, 
36.9; IR (film, NaCl) 3435, 3062, 3030, 2923, 1604, 1496, 1454, 1356, 1200, 1186, 1099, 
1048, 996, 911, 736, 698 cm-1; [α]D: (+) 39.1° (c 3.00, CHCl3); HRMS (ESI) calcd for 
C22H28NaO5 (M+Na) + 395.1829, found 395.1820. 
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Methyl 6-C-(benzyloxymethyl)-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside 
(1.75). Sodium hydride (86 mg, 2.15 mmol) as a 60% dispersion in mineral oil was added 
to a stirred 0 ºC DMF (7 mL) solution of alcohol 1.74 (320 mg, 0.86 mmol) and benzyl 
bromide (0.52 mL, 4.3 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred overnight. After diluting the mixture with diethyl ether (10 mL), 
it was quenched by careful addition of saturated NH4Cl solution (2 mL). The organic 
layer was separated, washed with saturated solution of NH4Cl (10 mL), brine (25 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by flash chromatography (hexanes:EtOAc, 4:1) to give tribenzyl ether 1.75 as a 
colorless oil, (364 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 7.45-7.28 (m, 15H), 4.89 (d, 
J = 12.2 Hz, 1H), 4.80 (d, J = 11.7 Hz, 1H), 4.74-4.68 (m, 2H), 4.68 (d, J = 3.6 Hz, 1H), 
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4.53 (br s, 2H), 3.97-3.91 (m, 2H), 3.66-3.57 (m, 2H), 3.51 (dd, J = 9.4, 3.6 Hz, 1H), 3.38 
(s, 3H), 2.11 (ddd, J = 12.8, 5.0, 2.1 Hz, 1H), 1.84-1.78 (m, 2H), 1.43 (q, J = 12.1 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 138.6, 138.3, 138.0, 128.0, 128.0, 127.6, 127.3, 
127.3, 127.2, 127.2, 127.1, 98.5, 80.3, 75.1, 72.9, 72.7, 72.1, 66.3, 63.8, 54.5, 37.3, 35.1; 
IR (film, NaCl) 3062, 3030, 2922, 2861, 1604, 1586, 1496, 1454, 1357, 1245, 1204, 
1188, 1099, 1048, 913, 783, 735, 698 cm-1; [α]D: (+) 40.0° (c 1.00, CHCl3); HRMS (ESI) 
calcd for C29H34O5Na (M +Na) + 485.2299, found 485.2275. 
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6-C-(Benzyloxymethyl)-4,6-dideoxy-2,3-di-O-benzyl-α,β-D-glucopyranoside (1.76). A 
diluted sulfuric acid (2 M, 34 mL) was added to a solution of tribenzyl ether 1.75 (600 
mg, 1.3 mmol) in acetic acid (130 mL). The resulting solution was heated for 18 hours at 
80 ºC. After removal of all volatiles under reduced pressure, the residue was dissolved in 
dichloromethane (150 mL). The organic phase was washed with saturated solution of 
NaHCO3 (50 mL), brine (50 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (hexanes:EtOAc, 
7:3) to give the hemiacetal 1.76 as a colorless oil (524 mg, 90%): 1H NMR (400 MHz, 
CDCl3) δ 7.38-7.30 (m, 15H), 5.23 (d, J = 3.6 Hz, 1H), 4.95-4.85 (m, 2H), 4.76-4.69 (m, 
2H), 4.61-4.58 (m, 1H), 4.52-4.50 (m, 2H), 3.66-3.56 (m, 3H), 3.52-3.47 (m, 1H), 2.16-
2.06 (m, 1H), 1.89-1.77 (m, 2H), 1.49-1.38 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 
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138.4, 138.3, 138.2, 138.1, 138.1, 137.9, 128.1, 128.0, 127.7, 127.6, 127.4, 127.4, 127.4, 
127.3, 127.2, 127.2, 127.2, 97.0, 91.7, 83.6, 80.2, 78.2, 74.9, 74.5, 72.9, 72.6, 71.7, 71.7, 
68.4, 66.2, 65.8, 64.6, 53.0, 36.6, 35.0; IR (film, NaCl) 3392, 3062, 3030, 2921, 2862, 
1496, 1454, 1362, 1207, 1096, 911, 736, 697 cm-1; [α]D: (+) 23.1° (c 2.00, CHCl3); 
LRMS (ESI) calcd for C28H32NaO5 (M+Na) + 471.2, found 471.2. 
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(3R,4S,6R)-3,4-Bis(benzyloxy)-6-(2-(benzyloxy)ethyl)-tetrahydropyran-2-one (1.56). 
4 Å Molecular sieves (1.0 g) were added to a stirred CH2Cl2 (10 mL) solution of the 
hemiacetal 1.76 (400 mg, 0.89 mmol). After 15 min, the mixture was cooled to 0 ºC, PCC 
(880 mg, 4.02 mmol) was then added, and the reaction mixture was stirred for 2 hours at 
0 ºC. After dilution with diethyl ether (10 mL) and pentane (10 mL), the mixture was 
filtered over Celite. The filter cake was washed with Et2O/hexane (1:1, 50 mL), and the 
combined filtrate was concentrated under reduced pressure. The residue was purified by 
flash chromatography (hexanes:EtOAc, 4:1) to give lactone 1.76 as a colorless oil, (280 
mg, 70%). 1H NMR (400 MHz, CDCl3) δ 7.45-7.31 (m, 15H), 5.07 (d, J = 11.6 Hz, 1H), 
4.77 (d, J = 11.6 Hz, 1H), 4.69-4.60 (m, 3H), 4.56 (d J = 11.8 Hz, 1H), 4.51 (d, J = 11.8 
Hz, 1H), 4.07 (d, J = 6.8 Hz, 1H), 3.96-3.90 (m, 1H), 3.74-3.67 (m, 1H), 3.65-3.60 (m, 
1H), 2.33 (ddd, J = 14.0, 5.6, 3.2 Hz, 1H), 2.06-1.89 (m, 2H), 1.77 (q, J = 12.0 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 169.9, 137.8, 137.4, 136.9, 128.1, 128.07, 128.0, 127.6, 
127.4, 127.3, 127.3, 79.0, 75.3, 73.7, 73.3, 72.8, 71.6, 65.3, 35.5, 34.6; IR (film, NaCl) 
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3063, 3030, 2924, 2865, 1745, 1496, 1454, 1392, 1212, 1179, 1101, 1028, 911, 737, 698 
cm-1; [α]D: (+) 69.4° (c 2.00, CHCl3); HRMS (ESI) calcd for C28H31O5 (M+H)+ 447.2166, 
found 447.2155. 
 
O OMe
OH
OH
HO
HO
1. SOCl2, Pyridine
2. NaI, MeOH, H2O
O OMe
OH
OH
Cl
Cl
86%
1.65 1.77  
 
Methyl 4,6-dichloro-4,6-dideoxy-α-D-glucopyranoside (1.77). Sulfuryl chloride (2.6 
mL, 32.4 mmol) was added dropwise to a vigorous stirred chloroform (10 mL) 
suspension of methyl α-D-glucopyranoside 1.65 (1.0 g, 5.15 mmol) and pyridine (4.4 mL, 
54.4 mmol) at -40 ºC. The reaction mixture was stirred for 3 hours and then it was 
allowed to warm to room temperature and stirred overnight. The mixture was diluted with 
chloroform (25 mL) and washed with 10% aqueous H2SO4 solution (5 mL), followed by 
saturated solution of NaHCO3 (5 mL) water (15 mL), and brine (15 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated under reduced pressure to yield 
an oily residue, which was dissolved in methanol (15 mL). To this mixture was added a 
solution of sodium iodide (1.12 g, 7.5 mmol) in MeOH/water (1:1, 2 mL). The resulting 
solution was left to stand for 8 hours and then neutralized with NaHCO3. Evaporation of 
all volatiles gave a residue, which was extracted with hot chloroform (25 mL) and hot 
ethyl acetate (25 mL). The combined organic layers were dried over MgSO4 and 
recrystallized (EtOAc/hexanes) to give dichloride 1.77 as colorless needles (1.02 g, 
86%): mp 156-157 ºC (EtOAc/hexanes), lit.48 119-121 ºC (petroleum ether/CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 4.73 (d, J = 5.2 Hz, 1H), 4.45 (d, J = 4.8 Hz, 1H), 4.15 (t, J = 
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4.86 Hz, 1H), 3.99 (dd, J = 13.2, 4.8 Hz, 1H), 3.78 (dd, J = 13.2, 5.2 Hz, 1H), 3.68 (dd, J 
= 7.6, 2.8 Hz, 2H), 3.43 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 101.6, 71.0, 70.0, 69.7, 
65.0, 55.9, 44.5; IR (film, NaCl) 3429, 2067, 1641, 1363, 1261, 1196, 1135, 1076, 1045, 
1032, 986 cm-1; [α]D: (+) 187.8° (c 2.00, H2O), lit.48 [α]D: (+) 121.0° (c 1.8, H2O). LRMS 
(ESI) calcd for C7H13Cl2O4 (M+H)+ 231.0, 233.0, found 231.1, 233.1. 
 
O OMe
OH
OH
Cl
Cl
H2, (90 psi)
Raney Ni, Et3N
MeOH
O OMe
OH
OH
Cl
70%
1.77 1.78  
 
Methyl 6-chloro-4,6-dideoxy-α-D-glucopyranoside (1.78). A solution of dichloride 1.77 
(1.00 g, 4.35 mmol) in MeOH (30 mL) containing triethylamine (1.3 mL, 9.3 mmol) and 
Raney-nickel (Raney2800, 2.00 g) was subjected to a hydrogen pressure of 90 psi for 24 
hours. Raney-nickel was filtered off, and the filtrate was concentrated under reduced 
pressure. Brine (10 mL) was added to the residue and the aqueous layer was extracted 
with warm ethyl acetate (15 mL) three times. The combined organic extracts were dried 
over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography (hexanes/EtOAc, 1:1) to give 1.78 as a white solid (596 mg, 
70%): mp 106-107 ºC, (hexanes/EtOAc), lit.49 110-111 ºC, (petroleum ether/EtOAc); 1H 
NMR (400 MHz, CDCl3) δ 4.85 (d, J = 4.0 Hz, 1H), 3.99 (ddt, J = 17.2, 5.6, 2.0 Hz, 1H), 
3.89 (ddd, J = 11.4, 9.2, 4.8 Hz, 1H), 3.58 (d, J = 5.2 Hz, 2H), 3.47 (s, 3H), 3.43 (dd, J = 
9.2, 3.6 Hz, 1H), 2.10 (ddd, J = 12.4, 4.8, 2.0 Hz, 1H), 1.53 (q, J = 12.0 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 99.3, 73.9, 68.3, 67.6, 55.1, 46.2, 35.1; IR (film, NaCl) 3306, 
2955, 2920, 1645, 1468, 1451, 1382, 1355, 1339, 1190, 1130, 1081, 1047, 906, 775, 
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729cm-1; [α]D: (+) 159.0° (c 0.50, CH3OH), lit.49 [α]D: (+) 165.0° (c 1.02, CH3OH). 
LRMS (ESI) calcd for C7H14ClO4 (M+H) + 196.1, 198.0, found 196.2, 198.1. 
 
O OMe
OBn
OBn
Cl
1.79
O OMe
OH
OH
Cl BnBr, NaH
DMF
96%
1.78  
Methyl 6-chloro-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside (1.79). Sodium 
hydride (500 mg, 12.5 mmol) as a 60% dispersion in mineral oil was added portionwise 
to a stirred DMF (12.5 mL) solution of diol 1.78 (980 mg, 5.0 mmol) and benzyl bromide 
(1.50 mL, 12.5mmol) at 0 ºC. The resulting suspension was allowed to warm up to room 
temperature and stirred overnight. The reaction mixture was then diluted with ether (25 
mL), and saturated solution of NH4Cl (25 mL) was added carefully. The organic layer 
was separated and washed with saturated solution of NH4Cl (25 mL), brine (25 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure gave a yellowish oil, 
which was purified by column chromatography (hexanes/EtOAc, 4:1) to give dibenzyl 
ether 1.79 as a colorless oil, (1.80 g, 96%). 1H NMR (400 MHz, CDCl3) δ 7.41-7.30 (m, 
10H), 4.87 (d, J = 12.0 Hz, 1H), 4.79 (d, J = 11.6 Hz, 1H), 4.73-4.69 (m, 3H), 4.00-3.94 
(m, 2H), 3.53 (d, J = 5.2 Hz, 2H), 3.50 (dd, J = 9.2, 3.6 Hz, 1H), 3.42 (s, 3H), 2.16 (ddd, 
J = 12.8, 4.8, 2.0 Hz, 1H), 1.52 (q, J = 12.0 Hz, 1H); 13C NMR(100 MHz, CDCl3) δ 
138.4, 138.1, 128.0, 128.0, 127.7, 127.4, 127.3, 127.2, 98.7, 79.9, 74.5, 73.0, 72.3, 67.0, 
54.9, 46.3, 34.5; IR (film, NaCl) 3030, 2919, 1496, 1454, 1372, 1354, 1199, 1182, 1111, 
1047, 999, 914, 737, 697 cm-1; [α]D: (+) 159.0° (c 2.00, CHCl3); HRMS (ESI) calcd for 
C21H25ClNaO4 (M+Na) + 399.1334, found 399.1330. 
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O OMe
OBn
OBn
Cl NaCN, TBAI
NMP, 60oC
O OMe
OBn
OBn
NC
37%
1.79 1.80  
 
Methyl 6-cyano-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside (1.80). NaCN (490 
mg, 10.0 mmol) and n-Bu4NI (3.70 g, 10.0 mmol) were added to a solution of chloride 
1.79 (376 mg, 1.0 mmol) in N-methylpyrrolidone (10 mL). The reaction mixture was 
heated to 60 ºC for 48 hours, after which it was diluted with ether (25 mL) and saturated 
solution of NaHCO3 (25 mL) was added. The organic layer was separated, washed with 
brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexanes/EtOAc, 4:1) to give 1.80 as a 
colorless oil, (136 mg, 37%); starting material 1.79 was recovered (154 mg, 41%). 1H 
NMR (400 MHz, CDCl3) δ 7.38-7.26 (m, 10H), 4.85 (d, J = 12.4Hz, 1H), 4.77 (d, J = 
11.6Hz, 1H), 4.69 (d, J = 12.4 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 4.66 (d, J = 3.6 Hz, 
1H), 4.03-3.90 (m, 2H), 3.48 (dd, J = 9.6, 3.6 Hz, 1H), 3.40 (s, 3H), 2.52-2.50 (m, 2H), 
2.16 (ddd, J = 12.8, 5.2, 2.4 Hz, 1H), 1.50 (q, J = 12.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 138.4, 138.1, 128.3, 128.28, 127.9, 127.7, 127.5, 116.7, 99.0, 79.8, 74.3, 73.3, 
72.6, 63.1, 55.4, 36.5, 23.7; IR (film, NaCl) 3063, 3031, 2925, 2252, 1722, 1602, 1496, 
1454, 1356, 1275, 1190, 1107, 1044, 919, 804, 739, 714, 699 cm-1; [α]D: (+) 23.2° (c 
1.75, CHCl3); HRMS (ESI) calcd for C22H26NO4 (M+H)+ 368.1856, found 368.1838. 
 
O OMe
OBn
OBn
NC 1) DIBAL-H, toluene
2) NaBH4, MeOH
O OMe
OBn
OBn
HO
67%
1.80 1.74  
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Methyl 6-C-(hydroxymethyl)-4,6-dideoxy-2,3-di-O-benzyl-α-D-glucopyranoside 
(1.74). DIBAL-H (0.6 mL of a 1 M in hexanes, 0.6 mmol) was added to a stirred 0 ºC 
toluene (5 mL) solution of nitrile 1.80 (184 mg, 0.5 mmol). After stirring for 30 min at 
that temperature, the reaction mixture was quenched by addition of methanol (1 mL), 
followed by addition of aqueous HCl solution (2 N, 1.0 mL). The mixture was stirred for 
45 min and filtered. After phase separation of the filtrate, the aqueous layer was extracted 
with diethyl ether (10 mL) three times. The combined organic phase was washed with 2N 
HCl solution (10 mL), saturated solution of NaHCO3 (10 mL), and water (10 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to afford a colorless 
syrup. This residue was dissolved in methanol (5 mL), and sodium borohydride (38 mg, 
1.0 mmol) was added to it. The mixture was stirred at room temperature for 30 min, 
before excess sodium borohydride was destroyed by the addition of acetone (1 mL). 
Evaporation under reduced pressure gave a residue, which was co-evaporated with 
methanol (5 mL) three times to remove boron by-products. The residue was dissolved in 
ethyl acetate (10 mL), washed with 2 N HCl solution (5 mL), saturated NaHCO3 solution 
(5 mL), and water (5 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The residue was purified by flash chromatography (hexanes/EtOAc, 1:1) to give alcohol 
1.74 as a colorless oil (125 mg, 67%).  
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Chapter Two 
Synthesis of Antisense cis- and trans-[4.3.0]Bicyclic Nucleosides 
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2.1 Introduction 
2.1.1 Antisense Therapies 
Disease symptoms are sometimes caused by the abnormal production of certain 
proteins, for example, Duchenne muscular dystrophy is caused by the absence of 
dystrophin, which is responsible for the growth of muscle fiber.  If the abnormal 
production of a specific protein can be prevented, then the corresponding diseases can be 
treated.  Traditional drug therapies are usually based on using rationally designed 
compounds to block or inhibit the disease-causing proteins (Figure 1).  In recent years, 
non-small molecule therapy has attracted the attention of many research groups and 
pharmaceutical companies and has been widely studied.  There are several approaches to 
this type of therapy including: antisense,1,2 antigen,3 ribozymes,3 micro RNA (miRNA),4 
short interfering RNA (siRNA),5 and aptamers.3  Targeting the disease-causing gene, the 
nucleic acid-based therapies aim to disturb undesired protein production at an early stage 
compared with traditional drug therapies,  thus, representing a new and promising trend 
in drug discovery (Figure 2).  
 
 
Figure 1: Traditional drug therapy. 
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Figure 2: Antisense therapy. 
 
Production of proteins in vivo involves two stages: 1) transcription – the process 
of converting DNA to messenger RNA (mRNA) and 2) translation – the process of 
converting mRNA into protein.  During transcription double stranded DNA is separated 
into two single strands of DNA, via the action of a helicase enzyme.  The unwinding and 
separation of the strands involves breaking hydrogen bonds between complementary base 
pairs.  Once separated, an enzyme known as RNA polymerase reads the single stranded 
DNA and creates a complementary RNA sequence known as messenger RNA.  The 
mRNA strand created during transcription is decoded in the ribosome to create a specific 
amino acid sequence that is eventually synthesized into a protein.   If this transcription / 
translation process is carried out on a disease gene, unwanted proteins will be synthesized 
that can cause debilitating symptoms.  
 
The basis of antisense therapy is to stop the translation of diseased mRNA.  If the 
DNA sequence of a disease gene is known, then a synthetic strand (oligonucleotide) of 
DNA or RNA can be created to bind to the mRNA.  If the binding event is successful, 
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mRNA cannot be transcribed, since it needs to be single stranded, and thus the production 
of the disease protein is shut off.   This binding mRNA can activate an enzyme called 
RNase H, which will ultimately degrade the mRNA complex before protein synthesis 
occurs (Figure 2).  
 
Antisense therapy has shown promise in combating different forms of cancer, 
HIV/AIDS, and other diseases.1  One antisense drug, Vitravene (fomivirsen) (Figure 3),6 
discovered at ISIS pharmaceuticals has been used in the treatment of cytomegalovirus 
retinitis (CMV), and was approved by the FDA in 1998.  Although this is the only 
licensed antisense drug, other antisense drug candidates are currently in the late-phase 
clinical trials.7  
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Figure 3: Stucture of Vitravene (fomivirsen). 
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2.1.2 Antisense Oligonucleotides 
The short nucleic acid strand used to bind to mRNA and terminate its translation 
into disease proteins was termed an antisense oligonucleotide.1  Due to the 
complementary  base sequence of these oligonucleotides to the gene’s mRNA sequence, 
which is known as a “sense” sequence, these nucleotides bear the name antisense.  In 
general, an antisense nucleotides consists of 12–21 nucleotides, and its composition can 
include both naturally occurring or chemically modified single-stranded nucleic acids.  
Due to the poor binding affinity to mRNA and insufficient stability and pharmacokinetics 
in biological systems, naturally occurring nucleotides are limited in their use in antisense 
technology and often, chemically modified nucleotides are required for the synthesis of 
functional antisense oligonucleotides as potential drug candidates.1  There are usually 
four potential ways to modify oligonucleotides (Figure 4).  
 
  
Figure 4: Modification of an oligonucleotide.1 
 
For the internucleotide linkage, there are usually two types:  phosphate and 
nonphosphate linkages. Phosphate containing oligonucleotides have been most widely 
studied, such as phosphodiesters (PO) 2.2, methylphosphonates 2.3, boranophosphates 
2.4, and phosphorothioates (PS) 2.5  (Figure 5).  Phosphorothioate (PS) 2.5 is the most 
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widely used phosphate linkage in present antisense drug candidates.  It increases the 
stability towards nucleolytic degradation, and PS oligodeoxynucleotides can efficiently 
promote cleavage of the target RNA by RNase H.1   
 
 
Figure 5: Examples of phosphate linkages.  
 
Base modification can also play an important role in nucleoside design. Purine 
and pyrimidine bases are important in hydrogen bonding in nucleic acids. The physical 
properties of oligonucleotides are highly sensitive to modification of the bases and thus 
modifying these bases can have a dramatic effect on the size, conformation, pKa and 
stereoelectronics of the molecules.8  For example, 5-(1-propynyl)-2´-deoxyuridine (2.6) 
can enhance the stability of a triple-helix complex relative to thymidine 2.7 (Figure 6).9  
This suggests that an SAR study on modified base analogs could be very useful to 
provide important information for optimum base design.  
 
  
Figure 6: C-5 Propynyl-modified nucleosides. 
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Conjugation of oligonucleotides with diverse moieties in various positions (such 
as 3´ position of sugar moiety) could alter the pharmacokinetic properties of 
oligonucleotide drugs (Figure 4).  Many conjugation strategies have been studied.  
Cholesterol conjugates are one of the most widely studied conjugates. For example, a 
3´,5´-bis-cholesteryl-conjugated phosphorothioate oligodeoxynucleotide ISIS-9389 
reported by Leiden/Amsterdam Center for Drug Research and ISIS Pharmaceuticals was 
found to result in almost complete hepatic uptake of the oligonucleotide in the rat.10 
 
In terms of the sugar modification, modification of the 2´-position of a sugar 
moiety has been one of the most successful strategies to increase the drug potential of 
oligonucleotides. Substitution at 2´-position with electron withdrawing group has been 
shown to increase the binding affinity (such as the 2´-fluoro modification, 2.8) and 
stability (such as the 2´-O-methyl and methoxyethyl modifications, 2.9) (Figure 7). An 
alternate strategy exists in restricting the conformation of nucleosides most often through 
the synthesis of bicyclic sugars. These conformationally restricted sugars can increase the 
stability of resulting oligonucleotides, and 2´,4´-bicyclic nucleic acids (2´,4´-BNAs) are 
prime examples of these. Within this class of (2´,4´-BNAs), “locked nucleic acids” 
(LNAs) which contain a 2′-O atom and 4′-C 2-atom bridge (Figure 8), are even more 
conformationally restricted. Wengel11 and Imanishi12 have independently reported on the 
thermal stability of bridged nucleic acids (2.10 and 2.11, Figure 8).  
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Figure 7: Modification of the 2′ position of the sugar portion of nucleosides. 
 
 
Figure 8: Locked nucleic acids (LNAs). 
 
In general, because of the flexibility of the furanose ring, it is inherently 
nonplanar. Most of nucleic acids exist in two types conformations: the 3′-endo 
conformation or the 2′-endo conformation (Figure 9).  When the major deviation is on the 
same side as the base and C4′–C5′ bond, the atom involved is termed endo, if it is on the 
opposite side, the atom will be termed exo. The 3′-endo conformation is sometimes 
termed as N (north) type conformation, and the 2′-endo conformation is termed as S 
(south) type conformation.13  The N and S type conformations are usually in fast 
equilibrium due to the low energy barrier between these two forms. The N-type 
conformation often exists in A-type duplexes, and the stereoisomeric S-type conformation 
often exists in B-type duplexes (Figure 9).13 
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Figure 9: Conformation of nucleoside sugar moieties and structures of A- and B-type 
duplexes.15 
 
For the β-D-LNA, the ribose sugar is locked by the bridge into a near perfect N 
type pucker conformation, while for the enantio-LNA (α-L-LNA), it is locked into an S 
type conformation (Figure 8).14 The N-type LNAs can form more stable duplexes with 
complementary single-stranded RNA, and S-type LNAs will form stable duplexes with 
single-stranded DNA.15  
 
Other than the 2´,4´-bicyclic nucleic acids (2´,4´-BNAs) that have already been 
discussed, different bi- and tricyclic nucleoside systems have been synthesized by 
Leumann,16,17,18 Imanishi,19 and Nielsen,20 all of which contain locked furanose rings 
(Figure 10) and have shown moderate improvements in stability and binding affinity. 
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Figure 10:  Examples of bi- and tricyclic LNAs. 
 
 
The work described in this chapter is a part of an ongoing collaboration that the 
Hanessian group has with ISIS pharmaceuticals to develop new antisense oligonucleotide 
candidates.  The cis-[4.3.0]bicyclic antisense nucleoside 2.17 and the diastereomeric 
trans-[4.3.0]bicyclic compound 2.18 were selected as designed  molecule targets for this 
project (Figure 11).  Leumann has reported a D-[4.3.0]bicyclic nucleoside 2.14 (Figure 
10)21 which demonstrated, in his system, that the cyclohexane ring does not obviously 
alter the nucleic acid binding affinity when compared with D-[3.3.0]bicyclic nucleoside 
2.12.  It is the O-5′ substituent of the cyclohexane ring, which is oriented in either an 
axial or equatorial position in solution, that has an effect on the binding affinity to the 
target mRNA.18  The major focus of the work described herein, is to synthesize and study 
diastereomeric [4.3.0]bicyclic  nucleosides 2.17 and 2.18 (Figure 11). 
 
  
Figure 11: cis- (2.17) and trans -[4.3.0]bicyclic nucleosides (2.18). 
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2.1.3 Retrosynthetic Analysis of Target Nucleosides 2.17 and 2.18 
It was envisaged that both bicyclic nucleosides 2.17 and 2.18 could be assembled 
from bicyclic carbohydrate derived building blocks, where the nucleobases of each target 
could be installed via a Vorbrüggen glycosylation (Scheme 17).  As such, both 
nucleoside targets could be simplified to sub-targets 2.19 and 2.24.  In the case of the cis-
bicyclic nucleoside analogue 2.17, specifically intermediate 2.19, retrosynthetic 
simplification to the bicyclic β-hydroxy ketone presented the opportunity to employ an L-
proline-catalyzed intramolecular aldol reaction in the forward direction and simplified the 
synthesis of 2.17 to diketone 2.20.   Diketone 2.20 could be taken back to the homoallylic 
alcohol 2.21, which could be further simplified to a key aldehyde intermediate 2.22 via a 
stereoselective Felkin-Anh controlled Sakurai allylation. The trans-bicyclic nucleoside 
2.18 could be prepared from 2.24 via a Vorbrüggen glycosylation and a RCM reaction. 
The synthesis of 2.24 is possible from diene 2.25, where it was envisaged that 
diastereoselective Sakurai allylation could be used to generate the homoallylic alcohol 
portion of 2.25, and a diastereoselective Grignard addition could be employed to furnish 
the allylic alcohol portion.  Due to the desire to have the opposite configuration at the 
tertiary alcohol bearing stereogenic center, it was reasoned that Grignard addition to a 
bicyclic ketone such as 2.26 should take place primarily from the less hindered exo-side 
of the bicyclic system.  Both syntheses can be derived from the common aldehyde 
intermediate 2.22, which could could be obtained from commercially available L-
arabinose (2.23). 
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Scheme 17:  Retrosynthetic analysis of cis- and trans-[4.3.0]bicyclic nucleosides. 
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2.2 Results and Discussion 
2.2.1 Synthesis of Key Aldehyde Intermediate 2.22 
As outlined in the retrosynthetic analysis above (Scheme 17), intermediate 
aldehyde 2.22 will play a pivotal role in the planned syntheses of both nucleoside targets.  
The synthetic plan hopes to capitalize on the matching stereochemistry of L-arabinose at 
C-4′ with 2.17 and 2.18, while the stereochemistry at C-3′ will come from 
diastereoselective reactions, such as the L-proline catalyzed aldol condensation and 
Grignard additions respectively.  The synthesis of key intermediate 2.23 commenced with 
the selective protection of the primary alcohol as the TBDPS ether 2.27 (Scheme 18).  
The C-1–C-2 diol system was selectively protected as an isopropylidene acetal to give the 
known acetonide 2.28,22 and the remaining secondary hydroxyl group was converted to 
the 2-methyl naphthyl ether to give 2.29 in 93% yield.  Cleavage of the silyl ether 
protecting group using TBAF afforded the free primary alcohol 2.30, which was 
subjected to a Parikh-Doering oxidation to give the key aldehyde intermediate 2.22.  
 
 
Scheme 18: Synthesis of intermediate aldehyde 2.22. 
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2.2.2 Key allylation 
With aldehyde intermediate 2.22 in hand, the next step was to test the key 
allylation reaction.  In order to generate both diastereomeric homoallylic alcohols with 
high selectivity and yield, several Lewis acids were screened (Table 4).  Analysis of the 
Felkin-Ahn model suggested that the (S)-configured alcohol would be favored when a 
Lewis acid such as BF3.Et2O were used.  Thus it was pleasing to find that treatment of 
aldehyde 2.22 with BF3.OEt2 and allyl trimethylsilane under standard Sakurai allylation 
conditions23 afforded the desired homoallylic alcohol 2.31 as virtually a single 
diastereomer (d.r. >20:1) in 89% yield.  The (R)-configured homoallylic alochol 2.32 
could be prepared under chelation-controlled conditions.  Using allyl tributyltin as 
nucleophile and TiCl4 as a Lewis acid, the designed product was obtained in 1:1 d.r. and 
50% yield.  The lower yield of this reaction is attributed to TiCl4 being a much stronger 
Lewis acid, which resulted in cleaveage of the acetonide group.  With ZnI2 an 82% 
chemical yield of allyl addition product was obtained, but the major diastereomer was 
2.31.  Switching to MgBr2.OEt2,24 resulted in a 1:1 d.r. and 86% yield. Futher 
optimization found that 3.0 equivalents of MgBr2.OEt2, with 2 equivalents of allyl 
tributyltin at –78 ºC gave 2.32 in 93% overall yield with 1:4 d.r. (74 % isolated yield, 
entry 5).  Notably, using allyl trimethylsilane instead of allyl tributyltin afforded a 
reversal in diastereoselectivity (d.r. 5:1).  Increasing the reaction temperature to 25 ºC 
favored the formation of 2.31 regardless of the choice of nucleophile.      
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Table 4: Screening of Lewis acids for Sakurai allylation. 
 
 
2.2.3 Completion of the Synthesis of cis-[4.3.0]Bicyclic Nucleoside 2.17 
 With an expedient and diastereoselective route to alcohol 2.31 in place, the desired 
secondary alcohol was protected as the benzyl ether 2.33.  Selective removal the naphthyl 
ether was achieved by DDQ oxidation and the resulting secondary alcohol was then 
oxidized to ketone 2.35 with PCC in 96% yield.  Wacker oxidation25 of the terminal 
olefin followed by a very mild and efficient L-proline-catalyzed intramolecular aldol 
reaction furnished the bicyclic ketol 2.37. With 2.37 in hand, the final synthesis of cis-
[4.3.0]bicyclic nucleoside 2.17 was achieved by Dr. Benjamin R. Schroeder.  Complete 
reduction of the ketone group of 2.37 to a methylene group required a three-step process 
that involved reduction to the alcohol, thiocarbamate formation, and finally a Barton-
McCombie deoxygenation26 to give 2.39.  Removal of the acetonide under mild acidic 
conditions and subsequent acetylation provided the Vorbrüggen glycosylation27 precursor 
2.40, which was treated with persilylated thymine and TMSOTf, followed by TBAF to 
O
H
O
O
NapO
HO
Lewis acids O
O
O
NapO
H O
O
O
NapO
H
2.31 2.322.22
HO HO
SiMe3
SnBu3
A
B
+
entry Nucleophile (equiv.) Lewis acids (equiv.) T (oC) d.r. (2.31:2.32)[a] Yield(%)[b]
A (1.75)1 BF3.OEt2 (2.0) -78 >20:1 89 [c]
3 B (2.0) ZnI2 (1.1) -78 5:1 82
2 B (2.0) TiCl4 (1.1) -78 1:1 50
4
A (2.0) MgBr2.OEt2 (3.0) 25 5:1
5
B (2.0) MgBr2.OEt2 (3.0) 25 2:1
6
B (2.0) MgBr2.OEt2 (1.1) -78 1:1 86
8
B (2.0) MgBr2.OEt2 (3.0) -78 1:4 93 [d]
9
B (2.0) MgBr2.OEt2 (5.0) -78 1:4 90
81
84
[a] d.r. was determined by 1H NMR of isolated mixture 2.31 and 2.32. [b] Isolated overall 
yield of 2.31 and 2.32. [c] Isolated yield of 2.31. [d] 74% yield of 2.32.
A (2.0) MgBr2.OEt2 (3.0) -78 5:17 77
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give afford nucleoside 2.41. Removal of the acetyl under basic conditions gave the trans-
diol 2.42, Selective deoxygenation at the C-2′ position with a second Barton-McCombie 
deoxygenation26 afforded 2.43. Cleavage of the benzyl ether of 2.43 and subsequent 
protected as a dimethoxytrityl ether furnished the cis-nucleoside target 2.17.  The 
compound will be used later in an oligonucleotide synthesis at ISIS Pharmaceuticals.   
  66 
 
Scheme 19: Completion of the synthesis of cis-[4.3.0]bicyclic nucleoside 2.17. 
 
 
O
H
O
O
NapO
HO O
O
O
NapO
HHO
BF3.OEt2
CH2Cl2, -78 oC
SiMe3
BnBr, NaH
1:1 THF-DMF
O
O
O
NapO
HBnO
O
O
O
O
HBnO
PdCl2 (10 mol%),
Cu(OAc)2 (20 mol%),
O2 (1 atm)
7:1 DMA-H2O
O
O
O
O
HBnOO O
O
O
HL-proline 
(30 mol%)
DMF
OH
BnO
O
1. Me4NBH(OAc)3
  HOAc, CH3CN
2.
N N
S
N N
DMAP, CH2Cl2
O
O
O
H
OH
BnO
ON
S
N
2.22 2.31 2.33
2.34 2.35
2.36 2.37
2.38
89% 94%
91%
    CH2Cl2
9:1 CH2Cl2-H2O
DDQ PCC, NaOAcO
O
O
HO
HBnO
96% 65%
84%
2.37
Bu3SnH, 
AIBN (10 mol%)
toluene, 110 oC
O
O
O
H
OH
BnO
1. DOWEX 50W-8X
    1:1 dioxane-H2O
2. Ac2O, pyridine
O
OAc
OAc
H
OH
BnO
N
N
OSiMe3
OSiMe3
TMSOTf
CH3CN, 0 to 50 oC;
then TBAF, THF
O
OAc
H
OH
BnO
N NH
O
O
1. K2CO3, MeOH
2.
N N
S
N N
DMAP, CH2Cl2
Bu3SnH, 
AIBN (10 mol%)
toluene ,110 oC
OH
OH
BnO
N NH
O
O
1. 10% Pd/C, H2, 
MeOH
DMTrCl, 
2,6-lutidine
    1:1 pyridine-CH2Cl2
OH
OH
DMTrO
N NH
O
O
O
O
H
OH
BnO
N NH
O
O
N
S
N
2.39
2.40 2.41
2.42
2.17
2.
2.43
Compounds from 2.38 to 2.17 were synthesized by Dr. Benjamin R. Schroeder
  67 
2.2.4 Completion of the Synthesis of trans-[4.3.0]Bicyclic Nucleoside2.18 
 Under chelation-controlled conditions, with 3 equiv. MgBr2.OEt2 and 2 equiv. 
allyl tributyltin at –78 ºC, the Sakurai allylation gave the desired homoallylic alcohol 2.32 
in 74% isolated yield. Protection of the secondary hydroxyl group as a benzyl ether 2.44, 
subsequent naphthyl ether cleavage by DDQ oxidation afforded 2.45 and oxidation the 
resulting secondary alcohol by PCC provided C 3′ ketone 2.46. A vinyl Grignard reagent 
addition at the ketone 2.46 gave the desired tertiary alcohol 2.47 in 91% yield, which 
agreed with the prediction that vinyl nucleophiles would attack from the beta-face of the 
furanose ring, the alpha-face being blocked by the acetonide at C 1′ and C 2′ position. 
Removal of the acetonide under the mild acidic conditions, followed by selective 
acetylation of the C 1′ and C 2′ diol gave 2.48 (>5:1, β-α isomer). Treatment of 2.48 with 
persilylated thymine and TMSOTf, followed by TBAF afforded the Vorbrüggen 
glycosylation27 product 2.49. With 2.49 in hand, the final synthesis of the trans-
[4.3.0]bicyclic nucleoside 2.18 was accomplished by Dr. Benjamin R. Schroeder. Ring-
Closing Metathesis of 2.49 using Grubbs’ 2nd generation catalyst successfully furnished 
the bicyclic skeleton 2.50. Hydrogenation the resulting alkene followed by the acetyl 
cleavage under basic condition afforded the cis-diol 2.52, which need be deoxygenated at 
C 2′ position. Treatment of 2.52 under the same conditions used in the previous cis-
oligonucleoside 2.17 synthesis, in the presence of 1,1′-thiocarbonyldiimidazole (TCDI) 
and imidazole, however, gave C 2′-C 3′ thiocarbonate ester instead of C 2′ thiocarbonyl 
imidazole. When the C 2′ secondary alcohol reacted with TCDI, it could further react 
with the C 3′ tertiary alcohol gave a thiocarbonate ester due to the cis stereochemistry of 
the diol. Finally we found that using the phenyl carbonothioate group could minimize the 
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formation of the thiocarbonate ester. Barton-McCombie deoxygenation was then 
effective in selectively deoxygenating the C 2′ alcohol of 2.53 to afford 2.54. Although 
it’s not routine, we were pleased to find that using of excess Bu3SnH in dilute solutions 
of phenyl carbothioate could afford up to 83% yield of the desired deoxynucleoside. 
Removal of benzyl group of 2.54 and subsequent protection of the resulting hydroxyl 
group as a dimethoxytrityl ether again afforded the trans-[4.3.0] bicyclic nucleoside 2.18. 
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Scheme 20: Completion of the synthesis of trans-[4.3.0]bicyclic nucleoside 2.18. 
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2.2.5 Discussion 
As mentioned previously, a cis-D-[4.3.0]bicyclic nucleoside has been reported by 
Leumann (Scheme 21)18 in which a RCM strategy was used to synthesize a cis-sugar-
scaffold. However, this route gave a mixture of products 2.57 and 2.58, where the 
required one (2.58) is the minor isomer. We utilized an alternate route (Schemes 19 & 
20) employing optimized Sakurai additions (2.22→2.31 and 2.22→2.32) to successfully 
to avoid this diastereoselectivity problem. 
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Scheme 21: Leumann’s synthesis of cis-D-[4.3.0]bicyclic nucleoside. 
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(2.18).  Both nucleosides are assembled to furnish the antisense oligonucleotides for 
further testing.  
 
2.3 Experimental Procedures 
 
General information: All non-aqueous reactions were run in flame-dried glassware 
under a positive pressure of argon. Anhydrous solvents were distilled under positive 
pressure of dry argon before use and dried by standard methods. THF, ether, DCM and 
toluene were dried by the SDS (Solvent Delivery System), commercial grade reagents 
were used without further purification. Reactions were monitored by S-2 analytical thin-
layer chromatography (TLC) performed on pre-coated, glass-backed silica gel plates. 
Visualization of the developed chromatogram was performed by UV absorbance (wave 
length: 254 nm), and staining TLC plates with aqueous cerium ammonium molybdate, 
iodine, or aqueous potassium permanganate solution. Flash chromatography was 
performed on 230-400 mesh silica gel with the indicated solvent systems. Melting points 
were recorded on BÜCHI Melting Point B-540. Infrared spectra were recorded on a 
Perkin-Elmer FTIR Paragon 1000 and were reported in reciprocal centimeters (cm-1). 
Nuclear magnetic resonance spectra (NMR) were recorded either on Bruker AV-300 
MHz and AV-400 MHz spectrometers. Chemical shifts for 1H NMR spectra are recorded 
in parts per million from tetramethylsilane with the solvent resonance as the internal 
standard (CDCl3 δ 7.27 ppm, CD3OD, δ 3.31 ppm). Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, 
m = multiplet, and br = broad), coupling constants were reported Hz, and integration. 
Chemical shifts for 13C NMR spectra are recorded in parts per million from 
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tetramethylsilane using the central peak of the solvent resonance as the internal standard 
(CDCl3, δ 77.00 ppm, CD3OD, δ 49.15 ppm). All spectra were obtained with complete 
proton decoupling. Optical rotations were determined in a 1 dm cell at 589 nm at 20 ºC 
(Perkin-Elmer 343). Data are reported as follows: [α]D, concentration (c in g/100 mL), 
and solvent. High-resolution mass spectra were performed using fast atom bombardment 
(FAB) or electrospray (ESI) techniques. Low-resolution mass spectra were obtained 
using electrospray ionisation technique (ESI). 
 
 
 
 
5-O-t-Butyldiphenylsilyl-α ,β-L-arabinofuranose (2.27). Imidazole (9.1g, 133.2 mmol) 
and t-butyldiphenylchlorosilane (17.2 mL, 66.6 mmol) were added sequentially to a DMF 
(132 mL) solution of L-arabinose 2.23 (10.0 g, 66.6 mmol). The resulting mixture was 
heated to 60 ºC and was stirred for 3 hours. After cooling to room temperature, the 
solution was poured into 1 M HCl (170 mL), extracted with diethyl ether (80 mL) three 
times. The combined organic phase was washed with water (160 mL), saturated soulution 
of NaHCO3 (160 mL) and brine (160 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography 
(hexane/EtOAc, 2:1 to 3:7) to give the product 2.27 as a colorless oil (13.2 g, 51%). 1H 
NMR (400 MHz, CD3OD) δ 7.75-7.70 (m, 4H), 7.45−7.37 (m, 6H), 5.22-5.17 [1H total 
sum. 5.22 (d, H-1β, J = 4.4 Hz), 5.17 (d, H-1α, J = 2.8 Hz), α,β-ratio ~ 2.1:1], 4.12-4.04 
(m, 2H), 3.94-3.89 (m, 1H), 3.87-3.75 (m, 2H), 1.05 (s, 9H); 13C NMR (100 MHz, 
CD3OD) α isomer δ 136.9, 136.9, 131.0, 128.9, 103.5, 85.0, 83.9, 77.9, 65.3, 27.4, 20.2; 
TBDPSCl
imidazole
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O
HO
OH
OH
HO
H O
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OH
OH
HO
H
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β isomer δ 134.7, 134.7, 131.0, 128.9, 97.7, 84.1, 78.8, 77.1, 67.1, 27.4, 20.2; HRMS 
(ESI) calcd for C21H32NO5Si (M+NH4)+ 406.2044, found 406.2031. 
 
 
 
5-O-t-Butyldiphenylsilyl-1,2-isopropylidene-β-L-arabinofuranose (2.28). Anhydrous 
copper (ΙΙ) sulfate (3.78 g, 23.7 mmol) and two drops of concentrated sulfuric acid were 
added sequentially to a acetone (75mL) solution of 2.27 (3.35 g, 8.6 mmol). The resulting 
mixture was stirred overnight and filtered through a pad of celite. The filtrate was 
concentrated under reduced pressure to a volume of ~ 10 mL and diluted with EtOAc (60 
mL). The solution was washed with saturated solution of NaHCO3 (25 mL), the aqueous 
phase was back-extracted with EtOAc (25 mL) three times. The combined organic 
extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexane/EtOAc, 6:1 to 3:1) to give the 
product 2.28 as a colorless oil (3.48 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.69-7.66 
(m, 4H), 7.44-7.37 (m, 6H), 5.90 (d, J = 4.0 Hz, 1H), 4.56 (d, J = 4.0 Hz, 1H), 4.46−4.45 
(m, 1H), 4.09−4.05 (m, 1H), 3.84-3.82 (m, 2H), 2.06 (s, 1H), 1.34 (s, 3H), 1.30 (s, 3H), 
1.07 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 135.6, 135.5, 133.2, 133.2, 129.8, 129.8, 
127.8, 112.5, 105.5, 82.4, 87.0, 69.2, 76.4, 63.7, 26.8, 26.1, 19.2; [α]D: -3.2° (c 1.2, 
CHCl3); HRMS (ESI) calcd for C24H36NO5Si (M+NH4)+ 446.2357, found 446.2370. 
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5-O-t-Butyldiphenylsilyl-1,2-isopropylidene-3-O-(2’-naphthylmethyl)-β-L-
arabinofuranose (2.29). 2.28 (12.84 g, 30.0 mmol) as a solution in THF-DMF (1:1, 18 
mL), and 2-(Bromomethyl) naphthalene (7.96 g, 36 mmol) were added sequentially to a 
0°C THF-DMF (1:1, 165 mL) mixture of Sodium hydride (1.44g, 36.0 mmol) as a 60% 
dispersion in mineral oil and tetrabutyl ammonium iodide (1.11 g, 3.0 mmol). The 
resulting suspension was allowed to warm up to room temperature and was stirred until 
the starting material was completely consumed by TLC analysis.  The reaction solution 
was cooled to 0 °C, quenched with MeOH (4.0 mL), and diluted with diethyl ether (500 
mL). The solution was washed with water (200 mL) two times, and the aqueous phase 
was separated and back-extracted with diethyl ether (100 mL) three times. The combined 
organic extracts were washed with saturated solution of NaHCO3 (200 mL) and brine 
(200 mL), then dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexane/EtOAc, 9:1) to give the product 
2.29 as a colorless oil (15.86 g, 93%). 1H NMR (400 MHz, CDCl3) δ 7.86-7.81 (m, 4H), 
7.74-7.66 (m, 4H), 7.51-7.33 (m, 9H), 5.95 (d, J = 4.0 Hz, 1H), 4.83 (d, J = 12.2 Hz, 1H), 
4.80 (d, J = 12.2 Hz, 1H), 4.75 (d, J = 4.0 Hz, 1H), 4.32-4-30 (m, 2H), 3.89-3.81 (m, 2H), 
1.37 (s, 3H), 1.33 (s, 3H), 1.04 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 135.6; 134.9, 
134.8, 133.2, 133.2, 133.1, 129.7, 129.7, 128.3, 127.9, 127.7, 127.7, 126.5, 126.1, 126.0, 
125.6, 112.4, 105.7, 85.3, 85.1, 82.8, 71.7, 63.4, 26.9, 26.7, 26.1, 19.1; [α]D: +5.7° (c 
0.87, CHCl3); HRMS (ESI) calcd for C35H44NO5Si (M+NH4)+ 586.2983, found 586.2995. 
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1,2-Isopropylidene-3-O-(2’-naphthylmethyl)-β-L-arabinofuranose (2.30). 
Tetrabutylammonium fluoride (0.48 mL, 1 M solution in THF, 0.48 mmol) was added to 
a THF (3.3 mL) solution of 2.29 (247 mg, 0.434 mmol) at room temperature. The 
resulting solution was stirred until the starting material was completely consumed by 
TLC analysis. The solution was quenched by dropwise addition of saturated solution of 
NaHCO3 (1 mL) and diluted with EtOAc (15 mL).  The solution was washed sequentially 
with saturated solution of NaHCO3 (3 mL) and brine (3 mL), then dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography (hexane/EtOAc, 2:1) to give the product 2.30 as a white solid, (131 mg, 
92%). When scale up to 2.29 (15.86g, 27.9 mmol) in THF (212 mL), with 
tetrabutylammonium fluoride (1M solution in THF) (30.7 mL, 30.7 mmol), 88% yield 
was obtained. mp: 83.1-85.0 °C. 1H NMR (400 MHz, CDCl3) δ 7.86-7.81 (m, 4H); 7.51-
7.46 (m, 3H), 5.98 (d, J = 4.0 Hz, 1H), 4.82-4.72 (m, 3H), 4.32-4.28 (m, 1H), 4.08 (dd, J 
= 2.8, 0.4 Hz, 1H), 3.84-3.75 (m, 2H), 2.94 (br s, 1H), 1.57 (s, 3H), 1.37 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 134.5, 133.0, 132.8, 128.1, 127.7, 127.5, 126.4, 126.0, 125.8, 
125.4, 112.6, 105.4, 85.4, 85.0, 82.6, 71.6, 62.4, 26.9, 26.1; IR (film) 3469, 2936, 1375, 
1080 cm-1; [α]D: −8.0° (c 1.65, CHCl3);  HRMS (ESI) calcd for C19H22O5Na (M+Na)+ 
353.1359, found 353.1368. 
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1,2-Isopropylidene-3-O-(2’-naphthylmethyl)-5-β-L-arabino-pentodialdo-1,4-
furanose (2.22). Hunig’s base (4.74 mL, 27.74 mmol) and SO3.pyridine (98%) (4.42 g, 
27.24 mmol) as a solution in DMSO (22.5 mL) were added sequentially to a –20 °C 
CH2Cl2-DMSO (9:1, 82.0 mL) solution of 2.30 (3.00 g, 9.08 mmol). The solution was 
stirred for 10 min and then partitioned between diethyl ether (150 mL) and ice-cold brine 
(300 mL). The aqueous layer was separated and back-extracted with diethyl ether (150 
mL) three times. The combined extracts were washed sequentially with 0.5 M HCl (150 
mL) three times, water (150 mL) and saturated solution of NaHCO3 (150 mL), then dried 
over MgSO4, filtered and concentrated under reduced pressure.  The residue was 
reconstituted in toluene three times and concentrated under reduced pressure to remove 
any residual pyridine.  The residue was dried under hi-vacuum and utilized without 
further purification as a colorless oil, (2.68 g, 90%). 1H NMR (400 MHz, CDCl3) δ 9.89 
(s, 1H), 7.92-7.83 (m, 4H), 7.57-7.50 (m, 3H), 6.18 (d, J = 3.6 Hz, 1H), 4.80 (d, J = 11.8 
Hz, 1H), 4.75 (d, J = 11.8 Hz, 1H), 4.72 (d, J = 3.6 Hz, 1H), 4.65 (s, 1H), 4.46 (s, 1H), 
1.52 (s, 3H), 1.36 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 201.5, 134.0, 133.1, 133.0, 
128.3, 127.8, 127.6, 126.7, 126.2, 126.1, 125.2, 112.0, 106.5, 88.6, 84.8, 82.8, 71.9, 26.0, 
25.4; IR (film) 2984, 1730, 1098 cm−1; [α]D : (+) 13.0° (c 0.37, CHCl3); HRMS (ESI) 
calcd for C19H20O5Na (M+Na)+ 351.1203, found 351.1205. 
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Homoallylic alcohol 2.31. BF3.OEt2 (1.16 mL, 9.24 mmol) was added to a stirred –78 °C 
anhydrous CH2Cl2 (75 mL) solution of aldehyde 2.22 (1.52 g, 4.62 mmol). After 5 min, 
allyl trimethylsilane (1.29 mL, 8.09 mmol) was added to this solution.  The resulting 
solution was stirred for 3 hours and quenched by dropwise addition of saturated solution 
of NaHCO3 (5 mL).  The solution was warmed to room temperature and partitioned 
between saturated solution of NaHCO3 (85 mL) and CH2Cl2 (85 mL).  The aqueous layer 
was separated and back-extracted with CH2Cl2 (50 mL) three times. The combined 
extracts were washed with brine (50 mL), then dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(hexane/EtOAc, 5:1) to give the product 2.31 as a colorless solid which crystallized upon 
standing, (3.63 g, 89%); mp = 74.0-78.0 °C. 1H NMR (400 MHz, CDCl3) δ 7.87-7.83 (m, 
4H), 7.52-7.48 (m, 3H), 5.97 (d, J = 3.9 Hz, 1H), 5.91-5.84 (m, 1H), 5.22-5.15 (m, 2H), 
4.82 (d, J = 11.6 Hz, 1H), 4.76 (d, J = 11.6 Hz, 1H), 4.73 (d, J = 3.9 Hz, 1H), 4.31 (d, J = 
2.4 Hz, 1H), 4.11-4.04 (dd, J = 4.2, 2.7 Hz, 1H), 3.94-3.89 (m, 1H), 2.56-2.49 (m, 1H), 
2.35 (br s, 1H), 2.28-2.20 (m, 1H), 1.56 (s, 3H), 1.37 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 134.6, 134.1, 133.1, 132.9, 128.1, 127.8, 127.6, 126.6, 126.0, 125.9, 125.6, 
118.2, 112.6, 105.5, 87.6, 84.7, 82.3, 71.6, 70.0, 37.5, 27.0, 26.0; IR (film) 3488, 3057, 
2984, 2936, 1383, 1375 cm−1; [α]D: (−) 3.4° (c 1.67, CHCl3); HRMS (ESI) calcd for 
C22H26O5Na (M+Na)+ 393.1673, found 393.1679. 
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Alkene 2.33. Sodium hydride (0.420 g, 10.5 mmol) as 60% dispersion in mineral oil and 
benzyl bromide (2.0 mL, 16.8 mmol) were added to a stirred 0 °C THF-DMF (1:1, 28 
mL) solution of homoallylic alcohol 2.31 (3.10 g, 8.4 mmol). The resulting mixture was 
allowed to warm to room temperature and stirred for 6 hours. The solution was cooled to 
0 °C and quenched with saturated solution of NH4Cl (5 mL) and partitioned between 
diethyl ether (100 mL) and water (100 mL).  The aqueous portion was separated and 
back-extracted with diethyl ether (100 mL) three times.  The combined extracts were 
washed sequentially saturated solution of NaHCO3 (100 mL), brine (100 mL), then dried 
over MgSO4, filtered and concentrated under reduced pressure.  The residue was purified 
by flash chromatography (hexane/EtOAc, 9:1) to give the product 2.33 as a colorless oil, 
(3.61 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.90-7.81 (m, 4H), 7.53-7.47 (m, 3H), 
7.32-7.28 (m, 5H), 6.02 (d, J = 3.7 Hz, 1H), 6.07-5.97 (m, 1H), 5.29-5.16 (m, 2H), 4.82-
4.70 (m, 4H), 4.55 (m, 1H), 4.25-4.19 (m, 2H), 3.83-3.78 (m, 1H), 2.71-2.65 (m, 1H), 
2.56-2.49 (m, 1H), 1.51 (s, 3H), 1.37 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.1, 
134.9, 133.9, 133.1, 132.9, 128.2, 128.1, 127.8, 127.8, 127.6, 127.5, 126.5, 126.0, 125.8, 
125.6, 117.8, 112.1, 105.8, 85.8, 84.9, 82.6, 77.4, 71.8, 71.3, 34.6, 26.8, 26.0; IR (film) 
3060, 3030, 1639, 746 cm−1; [α]D: (+) 22.8° (c 1.18, CHCl3); HRMS (ESI) calcd for 
C29H36O5N (M+NH4)+ 478.2588, found 478.2599. 
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Alcohol 2.34. DDQ (1.82 g, 8.0 mmol) was added to a stirred CH2Cl2-H2O (9:1, 110 mL) 
solution of naphthyl ether 2.33 (1.84 g, 4.0 mmol).  The resulting mixture was vigorously 
stirred until the starting material was complete consumed by TLC analysis.  The mixture 
was quenched by addition of a 10% solution of NaHSO3 (100 mL), and the aqueous 
portion was back-extracted with CH2Cl2 (50 mL) three times.  The combined extracts 
were washed sequentially with saturated solution of NaHCO3 (100 mL), brine (100 mL), 
then dried over MgSO4, filtered and concentrated under reduced pressure.  The residue 
was purified by flash chromatography (hexane/EtOAc, 3:1) to give the product 2.34 as a 
colorless oil, (1.17 g, 91%). 1H NMR (400 MHz, CDCl3) δ 7.37-7.27 (m, 5H); 5.97-5.88 
(m, 1H), 5.87 (d, J = 4.0 Hz, 1H), 5.22-5.12 (m, 2H), 4.70 (d, J = 11.2 Hz, 1H), 4.51 (d, J 
= 4.0 Hz, 1H), 4.48 (d, J = 11.2 Hz, 1H), 4.31 (t, J = 2.8 Hz, 1H), 3.85-3.82 (dd, J = 6.4, 
2.8 Hz, 1H), 3.77-3.73 (m, 1H), 2.81 (br s, 1H), 2.63-2.57 (m, 1H), 2.45-2.37 (m, 1H), 
1.44 (s, 3H), 1.29 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 137.8, 133.6, 128.4, 128.1, 
127.8, 118.0, 112.3, 105.5, 87.6, 86.7, 77.9, 76.3, 71.9, 34.5, 26.8, 26.0; IR (film) 3452, 
3067, 3031, 2982, 2939, 1640, 744 cm−1; [α]D: (+) 43.0° (c 1.41, CHCl3);  HRMS (ESI) 
calcd for C18H24O5Na (M+Na)+ 343.1516, found 343.1529. 
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Ketone 2.35. A CH2Cl2 (40 mL) solution of secondary alcohol 2.34 (1.94 g, 6.1 mmol) 
was added to a stirred 0 °C CH2Cl2 (160 mL) mixture of PCC (3.94 g, 18.3 mmol), 
anhydrous sodium acetate (1.53 g, 18.6 mmol) and activated 4 Å molecular sieves.  The 
resulting mixture was allowed to warm to room temperature and stirred for 3 hours. The 
solution was quenched with diethyl ether (200 mL) and was added silica gel (~ 4 g). 
After the mixture was stirred for 30 min, the mixture was filtered through a short pad of 
silica gel and eluted with diethyl ether (50 mL) three times. The combined filtrate was 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(hexane/EtOAc, 4:1) to give the product 2.35 as a colorless oil, (1.85 g, 96%). 1H NMR 
(400 MHz, CDCl3) δ 7.40-7.25 (m, 5H); 6.01 (d, J = 4.0 Hz, 1H), 5.92-5.82 (m, 1H), 
5.21-5.11 (m, 2H), 4.68 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.40 (d, J = 4.0 
Hz, 1H), 4.21 (d, J = 5.6 Hz, 1H), 3.87-3.83 (m, 1H), 2.55-2.50 (m, 2H), 1.49 (s, 3H), 
1.39 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 206.7, 137.5, 133.5, 127.9, 127.7, 127.3, 
117.3, 114.5, 102.2, 80.8, 78.2, 76.5, 72.0, 34.6, 26.5, 26.2; IR (film) 2988, 2938, 1770, 
1090, 1067 cm−1; [α]D: (+) 10.9° (c 0.42, CHCl3); HRMS (ESI) calcd for C18H22O5Na 
(M+Na)+ 341.1359, found 341.1364. 
 
 
 
Diketone 2.36. PdCl2 (0.007 g, 0.041 mmol) and Cu(OAc)2 (0.015 g, 0.082 mmol) were 
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sequentially added to a stirred DMA-H2O (7:1, 0.7 mL) solution of ketone 2.35 (0.13 g, 
0.41 mmol).  The resulting mixture was purged with O2 and maintained under an 
atmosphere of O2.  The mixture was vigorously stirred for 2 days and filtered through a 
pad of Celite.  The filtrate was partitioned between Et2O (10 mL) and H2O (10 mL).  The 
aqueous portion was separated and back-extracted with Et2O (10 mL) three times.  The 
combined extracts were washed with saturated solution of NaHCO3 (10 mL) and brine 
(10 mL), then dried over MgSO4, filtered and concentrated under reduced pressure.  The 
residue was purified by flash chromatography (hexane/EtOAc, 7:3) to give the product 
2.36 as a colorless oil, (0.088 g, 65%). 1H NMR (400 MHz, CDCl3) δ  7.36-7.25 (m, 5H), 
5.99 (d, 1H, J = 4.0 Hz), 4.69 (d, J = 11.2 Hz, 1H), 4.58 (d, J = 11.2 Hz, 1H), 4.40 (d, J = 
4.4 Hz, 1H), 4.38-4.33 (m, 1H), 4.20 (d, J = 5.6 Hz, 1H), 2.96-2.88 (m, 1H), 2.87-2.77 
(m, 1H), 2.15 (s, 3H), 1.51 (s, 3H), 1.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 206.8, 
206.1, 137.7, 128.1, 128.0, 127.6, 114.9, 102.4, 81.4, 76.8, 75.1, 73.4, 45.1, 30.8, 26.8, 
26.4; IR (film) 2990, 2940, 1770, 1716, 1069 cm−1; [α]D: (−) 18.9° (c 1.11, CHCl3); 
HRMS (ESI) calcd for C18H22O6Na (M+Na)+ 357.1309, found 357.1322. 
 
 
 
Ketol 2.37. L-proline (0.009 g, 0.076 mmol) was added to a stirred DMF (20 mL) 
solution of diketone 2.36 (0.085 g, 0.254 mmol). The resulting solution was stirred for 
three days and diluted with Et2O (30 mL).  The solution was washed with H2O (10 mL) 
and the aqueous layer was separated and back-extracted with Et2O (10 mL) three times.  
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The combined organic extracts were washed with saturated solution of NaHCO3 (10 mL),  
brine (10 mL), then dried over MgSO4, filtered and concentrated under reduced pressure.  
The residue was purified by flash chromatography (hexane/EtOAc, 3:2) to give the 
product 2.37 as a colorless oil, (0.072 g, 84%). 1H NMR (400 MHz, CDCl3) δ 7.35-7.24 
(m, 5H); 5.89 (d, J = 3.2 Hz, 1H), 4.69 (d, J = 12.4 Hz, 1H), 4.59 (d, J = 12.4 Hz, 1H), 
4.38 (d, J = 3.2 Hz, 1H), 4.14 (d, J = 4.0 Hz, 1H), 4.11-4.05 (m, 1H), 3.68 (br s, 1H), 3.21 
(d, J = 16.4 Hz, 1H), 2.70-2.64 (m, 1H), 2.38 (d, J = 16.4 Hz, 1H), 2.42-2.37 (m, 1H), 
1.47 (s, 3H), 1.32 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 208.3, 137.7, 128.3, 127.6, 
127.6, 115.1, 104.4, 89.2, 84.6, 77.9, 71.9, 71.4, 46.8, 39.6, 27.2, 26.8; IR (film) 3430, 
2986, 2935, 1715, 1373, 1098 cm−1; [α]D: (−) 68.3° (c 0.87, CHCl3); HRMS (ESI) calcd 
for C18H22O6Na (M+Na)+ 357.1309, found 357.1325. 
 
 
 
Homoallylic alcohol 2.32. MgBr2.OEt2 (0.155 g, 0.60 mmol) and allyltributyltin (0.129 
mL, 0.40 mmol) were added sequentially to a stirred –78 °C CH2Cl2 (1.8 mL) solution of 
aldehyde 2.22 (0.065 g, 0.20 mmol). The resulting solution was stirred for two hours and 
quenched with saturated solution of NaHCO3 (0.5 mL). The mixture was warmed to 
room temperature and partitioned between CH2Cl2 (5 mL) and saturated aq NaHCO3 (5 
mL).  The aqueous portion was separated and back-extracted with CH2Cl2 (5 mL) three 
times.  The combined extracts were washed with brine (5 mL), then dried over MgSO4, 
filtered and concentrated under reduced pressure.  The residue was purified by flash 
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chromatography (hexane/EtOAc, 4:1) to give the product 2.32 as a colorless oil. (0.055g, 
74%). 1H NMR (400 MHz, CDCl3) δ 7.89-7.74 (m, 4H), 7.51-7.44 (m, 3H), 5.95 (d, J = 
4.0 Hz, 1H), 5.93-5.80 (m, 1H), 5.14-5.08 (m, 1H), 5.06 (s, 1H), 4.81 (d, J = 12.0 Hz, 
1H), 4.73 (d, J = 4.0 Hz, 1H), 4.69 (d, J = 12.0 Hz, 1H), 4.06-3.99 (m, 2H), 3.75 (q, J = 
6.4 Hz, 1H), 2.54 (br s, 1H), 2.26 (t, J = 6.8 Hz, 2H), 1.54 (s, 3H), 1.36 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 134.4, 134.1, 133.2, 133.1, 128.4, 127.8, 127.7, 126.7, 126.2, 126.1, 
125.6, 117.6, 112.9, 105.4, 87.7, 85.2, 83.2, 71.9, 70.2, 38.1, 27.0, 26.3; IR (film) 3497, 
2983, 2936, 1374, 1073 cm−1; [α]D: −16.3° (c 1.32, CHCl3); HRMS (ESI) calcd for 
C22H26O5Na (M+Na)+ 393.1673, found 393.1678. 
 
 
 
Alkene 2.44. Sodium hydride (0.062g, 1.55 mmol) as a 60% dispersion in mineral oil and 
benzyl bromide (0.295 mL, 2.48 mmol) were added sequentially to a stirred 0 °C 
DMF−THF (1:1, 4.2 mL) solution of homoallylic alcohol 2.32 (0.458 g, 1.24 mmol). The 
mixture was allowed to warm to room temperature and was stirred for three hours. The 
solution was cooled to 0 °C and quenched with saturated solution of NH4Cl (1 mL) and 
partitioned between diethyl ether (20 mL) and H2O (20 mL).  The aqueous portion was 
separated and back-extracted with diethyl ether (10 mL) three times.  The combined 
extracts were washed sequentially with saturated solution of NaHCO3 (10 mL) three 
tomes and brine (10 mL), then dried over MgSO4, filtered and concentrated under 
reduced pressure.  The residue was purified by flash chromatography (hexane/EtOAc, 
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9:1) to give the product 2.44 as a colorless oil, (0.518 g, 91%). 1H NMR (400 MHz, 
CDCl3) δ 7.85-7.75 (m, 4H), 7.51-7.43 (m, 3H), 7.29-7.24 (m, 5H), 5.97-5.81 (m, 2H), 
5.15-5.04 (m, 2H), 4.81 (d, J = 11.6 Hz, 1H), 4.72 (dd, J = 3.2, 1.2 Hz, 1H), 4.59 (d, J = 
11.6 Hz, 2H), 4.573(d, J = 11.6 Hz, 1H), 4.05-4.01 (m, 2H), 3.63-3.58 (m, 1H), 2.41-2.37 
(m, 2H), 1.52 (s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.4, 134.6, 134.5, 
133.1, 133.1, 128.3, 128.2, 127.9, 127.9, 127.7, 127.4, 126.9, 126.1, 126.1, 125.8, 117.4, 
113.6, 104.8, 85.9, 84.9, 82.6, 77.8, 72.7, 72.0, 35.7, 27.4, 27.0; IR (film) 2936, 1373, 
1212, 1073 cm−1; [α]D : −30.4° (c 0.89, CHCl3); HRMS (ESI) calcd for C29H32O5Na 
(M+Na)+ 483.2142, found 483.2142. 
 
 
 
Alcohol 2.45. DDQ (0.050 g, 0.22 mmol) was added to a stirred CH2Cl2-H2O (9:1, 3.1 
mL) solution of 2.44 (0.052 g, 0.11 mmol). The mixture was vigorously stirred until 
complete consumption of the starting material by TLC analysis.  The mixture was 
quenched by addition of a 10% solution of NaHSO3 (2 mL), and the aqueous portion was 
back-extracted with three CH2Cl2 (5 mL) three times.  The combined extracts were 
washed sequentially with saturated aq NaHCO3 (5 mL) and brine (5 mL), then dried over 
MgSO4, filtered and concentrated under reduced pressure.  The residue was purified by 
flash chromatography (hexane/EtOAc, 7:3) to give the product 2.45 as a colorless oil: 
yield (0.026 g, 71%). 1H NMR (400 MHz, CDCl3) δ 7.42-7.24 (m, 5H), 5.98-5.90 (m, 
1H), 5.86 (d, J = 4.2 Hz, 1H), 5.21-5.10 (m, 2H), 4.72 (d, J = 11.7 Hz, 1H), 4.68 (d, J = 
O
O
O
NapO
HBnO
2.44 2.45
71%
9:1 CH2Cl2-H2O
DDQ O
O
O
HO
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11.7 Hz, 1H), 4.54 (dd, J = 3.0, 1.4 Hz, 1H), 4.24 (dd, J = 5.0, 1.4 Hz, 1H), 3.92-3.90 (m, 
1H), 3.75−3.71 (m, 1H), 2.53−2.36 (m, 2H), 2.03 (br s, 1H), 1.53 (s, 3H), 1.37 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 138.4, 134.6, 128.4, 128.0, 127.6, 117.5, 113.4, 104.6, 
87.8, 87.0, 77.9, 75.9, 73.0, 35.5, 27.4, 26.8; IR (film) 3436, 2985, 2938, 1384, 1374, 
1211, 1067 cm−1; [α]D: −9.2° (c 0.61, CHCl3); HRMS (ESI) calcd for C18H24O5Na 
(M+Na)+ 343.1516, found 343.1525. 
 
 
 
Ketone 2.46. A CH2Cl2 (4.4 mL) solution of alcohol 2.45 (0.205 g, 0.64 mmol) was 
added to a stirred 0 °C CH2Cl2 (17.6 mL) mixture of PCC (0.414 g, 1.92 mmol) and 
anhydrous NaOAc (0.160 g, 1.95 mmol).  The resulting mixture was allowed to warm to 
room temperature and was stirred for three hours.  The mixture was quenched upon 
addition of silica gel (0.1g), and was diluted with ethyl ether (30 mL). After the mixture 
was stirred for 30 min, it was filtered through a short plug of silica gel.  The filtrate was 
concentrated under reduced pressure, and the residue was purified by flash 
chromatography (hexane/EtOAc, 3:1) to give the product 2.46 as a colorless oil (0.164 g, 
91%). 1H NMR (400 MHz, CDCl3) δ 7.38−7.26 (m, 5H); 6.07 (d, J = 4.5 Hz, 1H), 
5.85−5.78 (m, 1H), 5.21 (m, 1H), 5.13 (m, 1H), 4.67 (d, J = 11.4 Hz, 1H), 4.61 (d, J = 
11.4 Hz, 1H), 4.42 (d, J = 4.2 Hz, 1H), 4.20 (d, J = 4.5 Hz, 1H), 3.87-3.83 (m, 1H), 2.57-
2.47 (m, 2H), 1.45 (s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 207.7, 137.9, 
133.7, 128.2, 128.0, 127.6, 118.3, 115.4, 102.5, 83.0, 77.8, 73.2, 35.1, 27.0, 26.9; IR 
O
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(film) 2987, 2939, 1769, 1375, 1218, 1160, 1089 cm−1; [α]D: −13.6° (c 0.73, CHCl3); 
HRMS (ESI) calcd for C18H22O5Na (M+Na)+ 341.1359, found 341.1359. 
 
 
 
Diene 2.47. Vinyl magnesium bromide (4.02 mL, 1.0 M solution in THF, 4.02 mmol) 
was added dropwise to a stirred 0 °C anhydrous THF (11 mL) solution of ketone 2.46 
(0.160 g, 0.50 mmol). The resulting solution was stirred at 0 °C for 10 min and quenched 
with saturated solution of NH4Cl (0.1 mL).  The mixture was partitioned between 
saturated solution of NH4Cl (5 mL) and EtOAc (5 mL).  The aqueous portion was 
separated and back-extracted with EtOAc (5 mL) three times.  The combined extracts 
were washed with brine (5 mL), then dried by MgSO4, filtered and concentrated under 
reduced pressure.  The residue was purified by flash chromatography (hexane/EtOAc, 
9:1) to give the product 2.47 as a colorless oil, (0.158 g, 91%). 1H NMR (400 MHz, 
CDCl3) δ 7.41-7.25 (m, 5H), 5.94-5.83 (m, 2H), 5.74 (d, J = 4.2 Hz, 1H), 5.48 (dd, J = 
15.6, 1.2 Hz, 1H), 5.23 (dd, J = 9.3, 1.2 Hz, 1H), 5.14-5.06 (m, 2H), 4.78 (d, J = 11.4 Hz, 
1H), 4.63 (d, J = 11.4 Hz, 1H), 4.39 (d, J = 4.2 Hz, 1H), 3.89-3.75 (m, 2H), 3.33 (s, 1H), 
2.57-2.50 (m, 1H), 2.27-2.20 (m, 1H), 1.67 (s, 3H), 1.46 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 140.4, 138.7, 134.6, 128.2, 128.1, 127.4, 117.3, 115.7, 114.7, 104.1, 87.2, 87.1, 
78.1, 77.2, 73.1, 35.4, 27.6, 27.4; IR (film) 3501, 2987, 2934, 1384, 1373, 1218, 1161, 
1106, 914, 873 cm−1; [α]D: +1.2° (c 0.26, MeOH); HRMS (ESI) calcd for C20H26O5Na 
(M+Na)+ 369.1673, found 369.1671. 
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Diacetate 2.48. DOWEX 50W-8X ionic exchange resin (0.094 g) was added to a 
dioxane-H2O (1:1, 5 mL) solution of diene 2.47 (0.094 g, 0.27 mmol). The resulting 
mixture was stirred for two days and filtered through a ground-glass frit.  The filtrate was 
partitioned between H2O (5 mL) and EtOAc (5 mL).  The aqueous portion was separated 
and back-extracted with EtOAc (10 mL) three times.  The combined organic portions 
were washed with saturated solution of NaHCO3 (5 mL) and brine (5 mL), then dried 
over MgSO4 and concentrated under reduced pressure.  The resultant colorless oil was 
reconstituted in pyridine (1 mL) and cooled to 0 °C.  To the solution was added acetic 
anhydride (0.076 mL, 0.81 mmol).  The solution was allowed to warm to room 
temperature and was stirred overnight under Argon.  The solution was diluted with 
EtOAc (5 mL), poured into ice water (5 mL), and extracted with EtOAc (10 mL) three 
times.  The combined organic extract was washed sequentially with saturated solution of 
NaHCO3 (5 mL) and brine (5 mL), then dried over MgSO4, filtered and concentrated 
under reduced pressure.  The residue was purified by flash chromatography 
(hexane/EtOAc, 3:1) to give the product 2.48 as a colorless oil, (0.091 g, 86%). 1H NMR 
(400 MHz, CDCl3) δ 7.35-7.27 (m, 5H), 6.27 (d, J = 3.6 Hz, 1H), 5.85-5.74 (m, 2H), 5.49 
(dd, J = 15.6, 1.6 Hz, 1H), 5.42-5.10 (m, 4H), 4.71 (d, J = 11.2 Hz, 1H), 4.66 (s, 1H), 
4.48 (d, J = 11.2 Hz, 1H), 4.08 (d, J = 2.8 Hz, 1H), 3.79 (ddd, app. dt, J = 6.8, 2.8, 2.8 
Hz, 1H), 2.53 (t, J = 7.2 Hz, 2H), 2.08 (s, 3H), 2.05 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 169.7, 169.5, 136.8, 136.6, 133.3, 128.5, 128.4, 128.1, 118.5, 117.1, 98.8, 82.7, 81.2, 
O
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80.7, 76.3, 71.8, 34.7, 21.1, 20.6; IR (film) 3435, 2980, 2920, 1751, 1372, 1221, 1071, 
1009, 954, 926 cm−1; [α]D: (−) 109° (c 1.35, CHCl3); HRMS (ESI) calcd for C21H26O7Na 
(M+Na)+ 413.1571, found 413.1563. 
 
 
 
Nucleoside 2.49. N,O-bis-trimethylsilyl acetamide (0.055 mL, 0.078 g, 0.385 mmol) was 
added to a stirred anhydrous acetonitrile (1.2 mL) mixture of thymine (0.020 g, 0.154 
mmol). The mixture was heated to 85 °C for one hour and then cooled to 0 °C.  To the 
solution was added diene 2.48 (0.030 g, 0.077 mmol) as a solution in anhydrous 
acetonitrile (1.2 mL) and TMSOTf (0.028 mL, 0.034 g, 0.154 mmol).  The solution was 
heated to 45 °C for 18 hours and then cooled to 0 °C and quenched with saturated 
solution of NaHCO3 (0.5 mL). The mixture was partitioned between (5 mL) ethyl acetate 
(5 mL) and saturated solution of NaHCO3 (5 mL).   The aqueous layer was separated and 
back-extracted with ethyl acetate (5 mL) three times.  The combined organic extracts 
were washed with brine (5 mL), then dried over MgSO4, filtered and concentrated under 
reduced pressure.  The residue was dried under hi-vacuum for 30 min and reconstituted in 
THF (1 mL).  To the solution was added TBAF (0.077 mL, 1M solution in THF, 0.077 
mmol).  The solution was stirred for 30 min and partitioned between EtOAc (5 mL) and 
saturated solution of NaHCO3 (5 mL).   The aqueous portion was separated and back-
extracted with EtOAc (5 mL) three times.  The combined extracts were washed with 
OH
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brine (5 mL), then dried over MgSO4, filtered and concentrated under reduced pressure.  
The residue was purified by flash chromatography (hexane/EtOAc, 1:2) to give the 
product 2.49 as a colorless foam, (0.022 mg, 65%). 1H NMR (400 MHz, CDCl3) δ 9.08 
(br s, 1H), 7.36-7.28 (m, 5H), 7.09 (d, J = 1.2 Hz, 1H), 5.82 (d, J = 5.6 Hz, 1H), 5.36 (d, 
J = 6.0 Hz, 1H), 4.67 (d, J = 12.4 Hz, 1H), 4.59 (d, J = 12.4 Hz, 1H), 4.56 (d, J = 3.2 Hz, 
1H), 3.87 (br, 1H), 3.70-3.64 (dt, J = 10.8, 3.6 Hz, 1H), 2.13 (s, 3H), 3.14 (s, 3H), 1.88-
1.85 (m, 1H), 1.75-1.49 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 172.3, 163.6, 138.2, 
126.7, 128.4, 127.7, 127.7, 111.6, 89.5, 85.2, 81.4, 78.2, 74.9, 70.8, 29.1, 25.4, 20.5, 19.0, 
12.6; IR (film) 3386, 3066, 1750, 1693, 1467, 1372, 1229, 1052 cm−1; [α]D: (−) 64.0° (c 
0.85, CHCl3); HRMS (ESI) calcd for C24H32N3O7 (M+NH4)+ 474.2235, found 474.2240. 
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